### Gene Level Meta-Analysis of Quantitative Traits by Functional Linear Models

Ruzong Fan,\*<sup>,1</sup> Yifan Wang,\* Michael Boehnke,<sup>†</sup> Wei Chen,<sup>‡</sup> Yun Li,<sup>§</sup> Haobo Ren,\*\* Iryna Lobach,<sup>††</sup> and Momiao Xiong<sup>‡‡</sup>

\*Biostatistics and Bioinformatics Branch, Division of Intramural Population Health Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland 20892, <sup>†</sup>Department of Biostatistics, School of Public Health, University of Michigan, Ann Arbor, Michigan 48109, <sup>‡</sup>Division of Pulmonary Medicine, Allergy, and Immunology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania 15224, <sup>§</sup>Department of Genetics, Department of Biostatistics, University of North Carolina, Chapel Hill, North Carolina 27599, \*\*Regeneron Pharmaceuticals, Basking Ridge, New Jersey 07920, <sup>††</sup>Division of Biostatistics, Department of Epidemiology and Biostatistics, University of California, San Francisco, California 94185, and <sup>‡‡</sup>Human Genetics Center, University of Texas, Houston, Texas 77225

**ABSTRACT** Meta-analysis of genetic data must account for differences among studies including study designs, markers genotyped, and covariates. The effects of genetic variants may differ from population to population, *i.e.*, heterogeneity. Thus, meta-analysis of combining data of multiple studies is difficult. Novel statistical methods for meta-analysis are needed. In this article, functional linear models are developed for meta-analyses that connect genetic data to quantitative traits, adjusting for covariates. The models can be used to analyze rare variants, common variants, or a combination of the two. Both likelihood-ratio test (LRT) and *F*-distributed statistics are introduced to test association between quantitative traits and multiple variants in one genetic region. Extensive simulations are performed to evaluate empirical type I error rates and power performance of the proposed tests. The proposed LRT and *F*-distributed statistics control the type I error very well and have higher power than the existing methods of the meta-analysis sequence kernel association test (MetaSKAT). We analyze four blood lipid levels in data from a meta-analysis of eight European studies. The proposed methods detect more significant associations than MetaSKAT and the *P*-values of the proposed LRT and *F*-distributed statistics are usually much smaller than those of MetaSKAT. The functional linear models and related test statistics can be useful in whole-genome and whole-exome association studies.

KEYWORDS meta-analysis; rare variants; common variants; association mapping; quantitative trait loci; complex traits; functional data analysis

**M**ETA-ANALYSIS is a statistical method to combine multiple studies for a unified analysis and it plays an important role in genetic studies (de Bakker *et al.* 2008; Zeggini and Ioannidis 2009; Cantor *et al.* 2010; Evangelou and Ioannidis 2013). One obvious advantage of meta-analysis is that the sample size is large (Liu *et al.* 2014). Therefore, metaanalysis should lead to more significant results. It is argued that most of the reported complex disease associations came from

Copyright © 2015 by the Genetics Society of America

doi: 10.1534/genetics.115.178343

Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD 20892. E-mail: fanr@mail.nih.gov

large-scale meta-analysis of genome-wide association studies (GWASs) (Zeggini and Ioannidis 2009; Evangelou and Ioannidis 2013; Liu *et al.* 2014). Therefore, there has been great interest in developing novel statistical methods to perform GWAS meta-analysis (Ioannidis *et al.* 2007; Hu *et al.* 2013; Liu *et al.* 2014). Meta-analysis combines studies with different study designs. The genotype data and covariates may vary from study to study. Moreover, the effects of genetic variants in different populations may not be the same, *i.e.*, the heterogeneity (Tang and Lin 2014). Thus, meta-analysis of combining data of multiple studies is difficult. Novel statistical methods for meta-analysis are needed.

The statistical methods for meta-analysis fall into two classes: (1) single genetic variant-based approaches and (2) gene-based variant analysis approaches. The single genetic variant approaches only use one genetic variant at a time and are usually based on fixed-effect linear regression models for

Manuscript received January 21, 2015; accepted for publication June 5, 2015; published Early Online June 9, 2015.

Supporting information is available online at www.genetics.org/lookup/suppl/ doi:10.1534/genetics.115.178343/-/DC1.

<sup>&</sup>lt;sup>1</sup>Corresponding author: 6100 Executive Blvd, Room 7B07J, MSC 7510, Biostatistics and Bioinformatics Branch, Division of Intramural Population Health Research, Eurice

quantitative traits,  $\chi^2$ -tests, or score tests for qualitative traits. The single genetic variant approaches are mainly applied to analyze common variants (Zeggini *et al.* 2008; Hindorff *et al.* 2009; Stahl *et al.* 2010). Gene-based approaches use multiple genetic variants in genetic regions in the analysis and can analyze rare variants, common variants, or combinations of the two. Developing gene-based approaches for association analysis is a major area of interest. A few recent studies have targeted analysis of rare variants.

Three types of tests are available for gene-based association analysis of complex diseases. The first type is burden tests that are based on collapsing rare variants in a genetic region to be a single variable that is then used to test for association with the phenotypes (Li and Leal 2008; Madsen and Browning 2009; Morris and Zeggini 2010; Price *et al.* 2010). Burden tests were built to analyze rare variants by aggregating statistics of multiple rare variants for an analysis.

The second type is variance-component tests such as the sequence kernel association test (SKAT) and its optimal unified version (SKAT-O) (Lee *et al.* 2012). In Lee *et al.* (2012), it was shown that SKAT-O has higher power than some burden tests, such as the combined collapsing and multivariate method (Li and Leal 2008) and the nonparametric weighted sum test (Madsen and Browning 2009). By extending SKAT and SKAT-O to perform meta-analysis, Lee *et al.* (2013) developed meta-analysis SKAT and SKAT-O (MetaSKAT and MetaSKAT-O) to carry out meta-analysis for rare variants in multiple studies. Both SKAT and MetaSKAT are score tests based on mixed-effect models.

The third type is tests based on fixed-effect models that include (1) traditional additive effect models that are well studied (Cordell and Clayton 2002; Fan and Xiong 2002; Fan et al. 2006) and (2) functional regression models as shown in our previous research (Luo et al. 2012; Fan et al. 2013, 2014; Wang et al. 2015). Note that functional regression models are fixed-effect models, which extend traditional population genetics models to analyze multiple genetic variants and can analyze rare variants, common variants, or combinations of the two. For individual studies with small and moderate sample sizes, functional linear models (FLMs) were proposed to analyze quantitative traits. The FLMs lead to  $\chi^2$ -score tests and *F*-distributed statistics, which are more powerful than SKAT and SKAT-O while controlling type I error correctly (Luo et al. 2012; Fan et al. 2013; Wang et al. 2015). For dichotomous traits, generalized FLMs were developed to perform gene-based association analysis (Fan et al. 2014).

In functional regression models, we treat multiple genetic variants of an individual as a realization of an underlying stochastic process (Ross 1996). Therefore, the genome of an individual in a chromosome region is a continuum of sequence data rather than discrete observations. The genome of an individual is viewed as a stochastic function that contains both genetic position and linkage disequilibrium (LD) information of the genetic markers. In short, the functional regression models have a number of advantages: (1) the genetic effects at the major gene locus are modeled as fixed effects, which fit traditional population genetics theory and modern genetic data very well; (2) the models fully utilize LD and genetic position information; and (3) the models test for a joint effect of genetic variants, including both common and rare.

It is worth of noting that SKAT and SKAT-O were found to perform better than C-alpha (Neale *et al.* 2011) and burden tests (Li and Leal 2008; Madsen and Browning 2009; Morris and Zeggini 2010; Price *et al.* 2010). Hence, FLMs are potentially very powerful in association analysis of complex quantitative traits. The superior performance of the FLMs motivates us to extend them to perform meta-analysis.

In this article, FLMs are developed for meta-analysis of multiple studies to connect genetic data to quantitative traits, adjusting for covariates. We allow that different studies may have different environmental factors/covariates, and genetic variants may differ among studies. The effects of genetic variants may differ from population to population, *i.e.*, heterogeneity. This makes it possible for us to build flexible models for meta-analysis of multiple studies. We assume that individual genotype data are available from all studies.

Both likelihood-ratio test (LRT) and *F*-distributed statistics of FLMs are introduced to test association between quantitative traits and multiple genetic variants in one gene region. Extensive simulations are performed to evaluate the empirical type I error rates and power performance of the proposed models and tests. The proposed methods are applied to analyze four blood lipid levels in data from metaanalysis of eight European studies.

#### **Materials and Methods**

Consider a meta-analysis with *L* studies in a genomic region. For the  $\ell$ th study, we assume that there are  $n_{\ell}$  individuals who are sequenced in the genomic region at  $m_{\ell}$  variants. We assume that the  $m_{\ell}$  variants are located with ordered genetic positions  $0 \le t_{\ell 1} < \cdots < t_{\ell m_{\ell}} \le T$ . To make the notation simpler, we normalized the region  $[t_{\ell 1}, T]$  to be [0, 1]. For the *i*th individual in the  $\ell$ th study, let  $y_{\ell i}$  denote her/his quantitative trait,  $G_{\ell i} = (X_{\ell i}(t_{\ell 1}), \cdots, X_{\ell i}(t_{\ell m_{\ell}}))'$  denote her/his genotypes of the  $m_{\ell}$  variants, and  $Z_{\ell i} = (z_{\ell i 1}, \cdots, z_{\ell i c_{\ell}})'$  denote her/his  $c_{\ell}$ covariates. Hereafter, ' denotes the transpose of a vector or matrix. For the genotypes, we assume that  $X_{\ell i}(t_{\ell j})$ (= 0, 1, 2) is the number of minor alleles of the individual *i* at the *j*th variant.

#### General functional linear model

In this section, we view the *i*th individual's genotype data as a genetic variant function (GVF)  $X_{\ell i}(t), t \in [0, 1]$ . Note that the sample includes  $n_{\ell}$  discrete realizations or observations  $G_{\ell i} = (X_{\ell i}(t_{\ell 1}), \dots, X_{\ell i}(t_{\ell m_{\ell}}))'$  of the human genome. By using the genetic variant information  $G_{\ell i}$ , we may estimate the related GVF  $X_{\ell i}(t)$ , which is discussed below. To relate the GVF to the phenotypic trait adjusting for covariates, we consider the following functional linear model,

$$y_{\ell i} = \alpha_{\ell 0} + Z'_{\ell i} \alpha_{\ell} + \int_{0}^{1} X_{\ell i}(t) \beta_{\ell}(t) dt + \varepsilon_{\ell i},$$
  

$$\ell = 1, 2, \cdots, L, \quad i = 1, 2, \cdots, n_{\ell},$$
(1)

where  $\alpha_{\ell 0}$  is the overall mean,  $\alpha_{\ell} = (\alpha_{\ell 1}, \dots, \alpha_{\ell c_{\ell}})'$  is a  $c_{\ell} \times 1$ column vector of regression coefficients of covariates,  $\beta_{\ell}(t)$  is the genetic effect of GVF  $X_{\ell i}(t)$  at the position t, and  $\varepsilon_{\ell i}$  is an error term. For each  $\ell$  and i, the error term  $\varepsilon_{\ell i}$  is normally distributed with a mean of zero and a variance  $\sigma_{e}^{2}$ . Moreover,  $\varepsilon_{\ell 1}, \dots, \varepsilon_{\ell n_{\ell}}$  are independent variables, and  $\varepsilon_{\ell} = (\varepsilon_{\ell 1}, \dots, \varepsilon_{\ell n_{\ell}})'$  are independent vectors of variables,  $\ell = 1, 2, \dots, L$ . Similar to the GVF, we assume that the genetic effect  $\beta_{\ell}(t)$  is a function of the genetic position t.

**Expansion of genetic effect function:** The genetic effect function  $\beta_{\ell}(t)$  is assumed to be smooth. One may expand it by B-spline or Fourier basis functions. Formally, let us expand the genetic effect function  $\beta_{\ell}(t)$  by a series of  $K_{\beta}$  basis functions  $\psi(t) = (\psi_1(t), \dots, \psi_{K_{\beta}}(t))'$  as  $\beta_{\ell}(t) = \psi(t)'\beta_{\ell}$ , where  $\beta_{\ell} = (\beta_{\ell 1}, \dots, \beta_{\ell K_{\beta}})'$  is a vector of coefficients  $\beta_{\ell 1}, \dots, \beta_{\ell K_{\beta}}$ . We consider two types of basis functions: (1) the B-spline basis,  $\psi_k(t) = B_k(t), k = 1, \dots, K_{\beta}$ ; and (2) the Fourier basis,  $\psi_1(t) = 1, \psi_{2r+1}(t) = \sin(2\pi r t)$ , and  $\psi_{2r}(t) = \cos(2\pi r t), r = 1, \dots, (K_{\beta} - 1)/2$ . Here for the Fourier basis,  $K_{\beta}$  is taken as a positive odd integer (de Boor 2001; Ramsay and Silverman 2005; Ferraty and Romain 2010; Horváth and Kokoszka 2012).

*Estimation of genetic variant function:* To estimate the genetic variant functions  $X_{\ell i}(t)$  from the genotypes  $G_{\ell i}$ , we use an ordinary linear square smoother (Ramsay and Silverman 2005; Ramsay *et al.* 2009; Fan *et al.* 2013). Let  $\phi_k(t), k = 1, \dots, K$ , be a series of *K* basis functions, such as the B-spline basis and Fourier basis functions. Denote  $\phi(t) = (\phi_1(t), \dots, \phi_K(t))'$ . Let  $\Phi$  denote the  $m_\ell$  by the *K* matrix containing the values  $\phi_k(t_{\ell j})$ , where  $j \in 1, \dots, m_\ell$ . Using the discrete realizations  $G_{\ell i} = (X_{\ell i}(t_{\ell 1}), \dots, X_{\ell i}(t_{\ell m_\ell}))'$ , we may estimate the GVF  $X_{\ell i}(t)$ , using an ordinary linear square smoother as follows (Ramsay and Silverman 2005, Chap. 4):

$$\hat{X}_{\ell i}(t) = (X_{\ell i}(t_{\ell 1}), \cdots, X_{\ell i}(t_{\ell m_{\ell}})) \Phi \left[ \Phi' \Phi \right]^{-1} \phi(t).$$
<sup>(2)</sup>

**Revised functional linear model:** We expand  $X_{\ell i}(t)$  by the ordinary linear square smoother. Assume that the genetic effect  $\beta_{\ell}(t)$  is expanded by a series of basis functions as  $\beta_{\ell}(t) = (\psi_1(t), \cdots, \psi_{K_{\beta}}(t))(\beta_{\ell 1}, \cdots, \beta_{\ell K_{\beta}})' = \psi(t)'\beta_{\ell}$ . Replacing  $X_{\ell i}(t)$  in the functional linear model (1) by  $\hat{X}_{\ell i}(t)$  in (2) and  $\beta_{\ell}(t)$  by the expansion, we have a revised linear regression model

$$\begin{aligned} y_{\ell i} &= \alpha_{\ell 0} + Z_{\ell i}' \,\alpha_{\ell} + \left[ (X_{\ell i}(t_{\ell 1}), \cdots, X_{\ell i}(t_{\ell m_{\ell}})) \Phi \left[ \Phi' \Phi \right]^{-1} \\ &\int_{0}^{1} \phi(t) \psi'(t) dt \right] \beta_{\ell} + \varepsilon_{\ell i} = \alpha_{\ell 0} + Z_{\ell i}' \alpha_{\ell} + W_{\ell i}' \beta_{\ell} + \varepsilon_{\ell i}, \end{aligned}$$

$$(3)$$

where  $W'_{\ell i} = (X_{\ell i}(t_{\ell 1}), \dots, X_{\ell i}(t_{\ell m_{\ell}})) \Phi[\Phi' \Phi]^{-1} \int_{0}^{1} \phi(t) \psi'(t) dt$ . In the above revised regression model, one needs to calculate  $\Phi[\Phi' \Phi]^{-1}$  and  $\int_{0}^{1} \phi(t) \psi'(t) dt$  to get  $W_{\ell i}$ . In the statistical packages R or Matlab, there are readily available codes to calculate them (Ramsay *et al.* 2009).

#### β-smooth only functional linear models

Model (1) is a theoretical FLM in functional data analysis literature (Ramsay and Silverman 2005). For analysis of dense genetic data, one may use a simplified model,

$$y_{\ell i} = \alpha_{\ell 0} + Z'_{\ell i} \, \alpha_{\ell} + \sum_{j=1}^{m_{\ell}} X_{\ell i}(t_{\ell j}) \beta_{\ell}(t_{\ell j}) + \varepsilon_{\ell i},$$
  
$$\ell = 1, 2, \cdots, L, \quad i = 1, 2, \cdots, n_{\ell},$$
 (4)

where  $\beta_{\ell}(t_{\ell j})$  is the genetic effect at the position  $t_{\ell j}$  for the  $\ell$ th study, and the other terms are similar to those in the general model (1). In the above model, the integration term  $\int_{0}^{1} X_{\ell i}(t) \beta_{\ell}(t) dt$  in model (1) is replaced by the summation term  $\sum_{j=1}^{m_{\ell}} X_{\ell i}(t_{\ell j}) \beta_{\ell}(t_{\ell j})$ . It turns out that model (4) performs very similarly to model (1) in real data analysis and simulations due to high resolution of genotype data (Fan *et al.* 2013, 2014; Wang *et al.* 2015).

In model (4),  $\beta_{\ell}(t_{ij})$  is introduced as the genetic effect at the position  $t_{ij}$ . We assume that the genetic effect function  $\beta_{\ell}(t)$  is a function of the genetic position t. Therefore,  $\beta_{\ell}(t_{ij}), j = 1, 2, \dots, m_{\ell}$ , are the values of function  $\beta_{\ell}(t)$  at the  $m_{\ell}$  genetic positions. The genetic effect function  $\beta_{\ell}(t)$  is assumed to be smooth. One may expand it by B-spline or Fourier basis functions as above. Replacing  $\beta_{\ell}(t_{ij})$  by the expansion, model (4) can be revised as

$$y_{\ell i} = \alpha_{\ell 0} + Z'_{\ell i} \,\alpha_{\ell} + \left[\sum_{j=1}^{m_{\ell}} X_{\ell i}(t_{\ell j}) \left(\psi_{1}(t_{\ell j}), \cdots, \psi_{K_{\beta}}(t_{\ell j})\right)\right] \\ \times \left(\beta_{\ell 1}, \cdots, \beta_{\ell K_{\beta}}\right)' + \varepsilon_{\ell i} = \alpha_{\ell 0} + Z'_{\ell i} \alpha_{\ell} + W'_{\ell i} \beta_{\ell} + \varepsilon_{\ell i},$$

$$(5)$$

where  $W_{\ell i} = \sum_{j=1}^{m_{\ell}} X_{\ell i}(t_{\ell j})(\psi_1(t_{\ell j}), \cdots, \psi_{K_{\beta}}(t_{\ell j}))$ . In model (4) and its revised version (5), we use the raw genotype data  $G_{\ell i} = (X_{\ell i}(t_{\ell 1}), \cdots, X_{\ell i}(t_{\ell m_{\ell}}))'$  directly in the analysis. The genetic effect function  $\beta_{\ell}(t)$  is assumed to be smooth. Hence, the models are called  $\beta$ -smooth only.

#### Traditional additive effect models

Traditionally, an additive effect model can be used to analyze the relation between the trait and the  $m_{\ell}$  variants in the  $\ell$  study as

$$y_{\ell i} = \alpha_{\ell 0} + Z'_{\ell i} \, \alpha_{\ell} + \sum_{j=1}^{m_{\ell}} X_{\ell i}(t_{\ell j}) \beta_{\ell j} + \varepsilon_{\ell i},$$
  
$$\ell = 1, 2, \cdots, L, \quad i = 1, 2, \cdots, n_{\ell},$$
(6)

(Fan and Xiong 2002; Fan *et al.* 2006), where  $\beta_{\ell j}$  is the additive genetic effect of variant *j* for the  $\ell$ th study, and the other terms are similar to those in the functional linear

models (1) and (4). There is only one difference between model (4) and model (6); *i.e.*, the genetic effect coefficients  $\beta_{ij}$  in model (6) do not depend on the genetic position  $t_{ij}$ , while  $\beta_{\ell}(t_{ij})$  in model (4) depend on the genetic position  $t_{ij}$ . The genetic effect coefficients  $\beta_{ij}$  in model (6) are discrete, while  $\beta_{\ell}(t_{ij})$  in model (4) are the values of function  $\beta_{\ell}(t)$  at the genetic positions  $t_{ij}$ ,  $j = 1, 2, \dots, m_{\ell}$ .

The number of parameters of model (6) can be large, and so it may not be powerful. Moreover, model (6) can model only the LD between the trait and each of the genetic variants as well as the pairwise LD between the genetic variants, but it cannot model higher-order LD among the genetic variants (Fan and Xiong 2002; Fan *et al.* 2006). In spite of the potential drawbacks, model (6) can be easily implemented by standard statistical software such as R, and we use it to make comparison with models (1) and (4). To facilitate the computation in applications, the QR decomposition can be applied to the genotype data to remove the redundancy if the number of genetic variants is large, i.e., to decompose the genotype matrix into the product of an orthogonal matrix Q and a triangular matrix R via Gram-Schmidt process.

One common feature of models (1), (4), and (6) is that they are all fixed-effect models. The novel part of models (1) and (4) is that we may revise them to be models (3) and (5) by functional data analysis techniques, in which the numbers *K* and  $K_\beta$  of basis functions do not depend on the numbers  $m_\ell$  of genetic variants. This makes models (1) and (4) able to conveniently analyze high-dimension genetic variant data.

#### LRT and F-distributed statistics

We consider the revised regression models (3) and (5) as usual multiple linear regressions. First, assume that the genetic effects among the *L* studies are different/ heterogeneous. To test the association between the genetic variants and the quantitative trait, the null hypothesis is  $H_0 : \beta_\ell = (\beta_{\ell 1}, \dots, \beta_{\ell K_\beta})' = 0, \ell = 1, \dots, L$ . By using the standard statistical approach, we may test the null  $H_0 : \beta_\ell = 0$  by a LRT and an *F*-distributed statistics. The LRT statistic is  $\chi^2$  distributed with  $LK_\beta$  d.f. and is denoted as Het-LRT. The *F*-distributed statistic's degrees of freedom (d.f.) are  $(LK_\beta, \sum_{\ell=1}^L (n_\ell - K_\beta) - 1)$  (Weisberg 2005). The *F*-distributed statistic is denoted as Het-F.

If the genetic effects are homogeneous, *i.e.*,  $\beta_{\ell} = (\beta_{\ell 1}, \dots, \beta_{\ell K_{\beta}})' = \beta = (\beta_1, \dots, \beta_{K_{\beta}})', \ell = 1, \dots, L$ , we may test the association between the genetic variants and the quantiative trait by testing a simplified null  $H_0 : \beta = (\beta_1, \dots, \beta_{K_{\beta}})' = 0$ . Again, a LRT and an *F*-distributed statistics can be used to test the null  $H_0 : \beta = (\beta_1, \dots, \beta_{K_{\beta}})' = 0$ . The *F*-distributed statistic has d.f.  $(K_{\beta}, \sum_{\ell=1}^{L} n_{\ell} - K_{\beta} - 1)$ . The *F*-distributed statistic is denoted as Hom-F. The LRT is  $\chi^2$  distributed with  $K_{\beta}$  d.f. and is denoted as Hom-LRT.

For the additive effect model (6), the null hypothesis of no association between the genetic variants and the quantitative trait is  $H_0$ :  $\beta_{\ell} = (\beta_{\ell 1}, \dots, \beta_{\ell m_{\ell}})' = 0, \ell = 1, \dots, L$ , un-

der an assumption of heterogeneous genetic effect. The corresponding LRT statistic is  $\chi^2$  distributed with  $\sum_{\ell=1}^{L} m_{\ell}$  d.f., and the corresponding *F*-distributed statistic has d.f. as  $(\sum_{\ell=1}^{L} m_{\ell}, \sum_{\ell=1}^{L} (n_{\ell} - m_{\ell}) - 1)$ . The tests are denoted as Het-LRT and Het-F.

Assume that each individual of the *L* studies is sequenced at the same variants located at  $0 \le t_1 < \cdots < t_m$  and so  $m_1 = \cdots = m_\ell = m$ . In addition, assume that the genetic effects are homogenous; *i.e.*,  $\beta_\ell = (\beta_{\ell 1}, \cdots, \beta_{\ell m_\ell})' = \beta = (\beta_1, \cdots, \beta_m)'$ . Then, model (6) is simplified as

$$y_{\ell i} = \alpha_{\ell 0} + Z'_{\ell i} \alpha_{\ell} + \sum_{j=1}^{m} X_{\ell i}(t_j) \beta_j + \varepsilon_{\ell i},$$
  
$$\ell = 1, 2, \cdots, L, \quad i = 1, 2, \cdots, n_{\ell}.$$
 (7)

The null hypothesis of no association between the genetic variants and the quantitative trait is  $H_0: \beta = (\beta_1, \dots, \beta_m)' = 0$ . The corresponding LRT statistic is  $\chi^2$  distributed with *m* d.f., and the corresponding *F*-distributed statistic has d.f. as  $(m, \sum_{\ell=1}^{L} n_\ell - m - 1)$ . The tests are denoted as Hom-LRT and Hom-F.

#### Parameters of functional data analysis

In the data analysis and simulations, we used the functional data analysis procedure in the statistical package R. We use two functions in library fda of the R package as follows to create basis:

basis = create.bspline.basis(norder = order, nbasis = bbasis) basis = create.fourier.basis(c(0,1), nbasis = fbasis).

The three parameters were taken as order = 4, bbasis = 15, fbasis = 25 in all data analysis. In the simulations, the three parameters were taken as order = 4, bbasis = 15, fbasis = 21 for the heterogeneous genetic effect model and order = 4, bbasis = 15, fbasis = 25 for the homogeneous genetic effect model. Specifically, the order of B-spline basis was 4, the number of basis functions of B-spline was  $K = K_{\beta} = 15$  and the number of Fourier basis functions was  $K = K_{\beta} = 21$  for the heterogeneous genetic effect model, and similarly the number of basis functions of B-spline was  $K = K_{\beta} = 15$  and the number of basis functions of B-spline was  $K = K_{\beta} = 15$  and the number of basis functions of B-spline was  $K = K_{\beta} = 15$  and the number of basis functions of B-spline was  $K = K_{\beta} = 15$  and the number of basis functions of B-spline was  $K = K_{\beta} = 25$  for the homogeneous genetic effect model.

To make sure that the results are valid and stable, we tried a wide range of parameters: (1)  $10 \le K = K_{\beta} \le 23$  for the heterogeneous genetic effect model and (2)  $10 \le K = K_{\beta} \le 29$  for the homogeneous genetic effect model. The results are similar to each other.

#### Results

#### Meta-analysis of lipid traits in eight European cohorts

Lipid traits from eight European cohorts were analyzed: five from Finnish (FUSION Stage 2, D2d-2007, DPS, METSIM, and DRs EXTRA), two from Norway (HUNT and Tromso),

Table 1 Association analysis of lipid traits in eight European cohorts by homogeneous likelihood-ratio tests (Hom-LRT), Hom-MetaSKAT-O, and Hom-MetaSKAT

				P-values of Hom	-LRT			
		Basis of both	GVF and $oldsymbol{eta}_\ell(t)$	Basis of $\beta$ -s	mooth only		P-values of	Hom-Meta-
Traits	Gene	B-spline basis	Fourier basis	B-spline basis	Fourier basis	Additive model (7)	SKAT	SKAT-O
HDL	LPL	$3.06 \times 10^{-6}$	$6.13\times10^{-9}$	$3.64  imes 10^{-6}$	$6.75 \times 10^{-7}$	$8.32 \times 10^{-4}$	$1.08 \times 10^{-3}$	$1.21 \times 10^{-3}$
LDL	APOB APOE LDLR PCSK9	$\begin{array}{c} 3.35\times10^{-9}\\ 1.27\times10^{-87}\\ 8.25\times10^{-15}\\ 2.29\times10^{-6} \end{array}$	$\begin{array}{c} 7.50 \times 10^{-4} \\ \textbf{3.42} \times \textbf{10^{-91}} \\ \textbf{1.67} \times \textbf{10^{-14}} \\ \textbf{5.36} \times \textbf{10^{-10}} \end{array}$	$\begin{array}{c} 5.76 \times 10^{-8} \\ 4.07 \times 10^{-83} \\ 5.09 \times 10^{-15} \\ 1.65 \times 10^{-6} \end{array}$	$\begin{array}{c} 1.87 \times 10^{-4} \\ \textbf{4.42} \times \textbf{10^{-90}} \\ \textbf{9.24} \times \textbf{10^{-14}} \\ \textbf{1.27} \times \textbf{10^{-7}} \end{array}$	$3.84 \times 10^{-5}$ 4.23 × 10 <sup>-89</sup> 7.14 × 10 <sup>-17</sup> 2.35 × 10 <sup>-17</sup>	$\begin{array}{c} 1.63 \times 10^{-2} \\ 1.18 \times 10^{-43} \\ 1.03 \times 10^{-10} \\ 6.18 \times 10^{-7} \end{array}$	$2.51 \times 10^{-2} \\ 6.67 \times 10^{-44} \\ 2.94 \times 10^{-10} \\ 2.00 \times 10^{-6} \\ \end{array}$
TG	APOE LPL	$4.95 \times 10^{-6} \\ 2.03 \times \mathbf{10^{-11}}$	$6.61  imes 10^{-6}$ <b>7.48</b> $ imes$ <b>10</b> <sup>-13</sup>	$\begin{array}{c} 5.13 \times 10^{-7} \\ 2.60 \times 10^{-11} \end{array}$	$\begin{array}{c} 1.90 \times 10^{-6} \\ 4.23 \times 10^{-14} \end{array}$	$\begin{array}{c} 1.37 \times 10^{-6} \\ 5.52 \times 10^{-7} \end{array}$	$1.34 \times 10^{-3}$ $1.78 \times 10^{-5}$	$2.59 \times 10^{-3}$ $1.77 \times 10^{-5}$
CHOL	APOB APOE HNF1A LDLR	$\begin{array}{c} 1.98 \times 10^{-8} \\ 2.48 \times 10^{-53} \\ 1.08 \times 10^{-1} \\ 8.10 \times 10^{-11} \end{array}$	$7.88 \times 10^{-3}$ 3.12 × 10 <sup>-53</sup> 1.84 × 10 <sup>-2</sup> 8.49 × 10 <sup>-10</sup>	$\begin{array}{c} \textbf{2.19}\times\textbf{10}^{-7} \\ \textbf{1.52}\times\textbf{10}^{-48} \\ \textbf{8.94}\times\textbf{10}^{-3} \\ \textbf{8.59}\times\textbf{10}^{-10} \end{array}$	$\begin{array}{c} 1.16 \times 10^{-4} \\ 1.36 \times 10^{-51} \\ 2.84 \times 10^{-6} \\ 6.68 \times 10^{-9} \end{array}$	$\begin{array}{c} \textbf{6.60} \times \textbf{10^{-8}} \\ \textbf{1.98} \times \textbf{10^{-51}} \\ \textbf{1.74} \times \textbf{10^{-1}} \\ \textbf{2.07} \times \textbf{10^{-12}} \end{array}$	$6.17 \times 10^{-2}$ 9.08 × 10 <sup>-23</sup> $1.89 \times 10^{-1}$ 3.43 × 10 <sup>-7</sup>	$\begin{array}{c} 1.00 \times 10^{-1} \\ \textbf{2.15} \times \textbf{10}^{-22} \\ 2.77 \times 10^{-1} \\ \textbf{1.15} \times \textbf{10}^{-6} \end{array}$

The associations that attain a threshold significance of  $P < 3.1 \times 10^{-6}$  are boldface (Liu *et al.* 2014). The results of "Basis of both GVF and  $\beta_{\ell}(t)$ " were based on smoothing both GVF and genetic effect functions  $\beta_{\ell}(t)$  of model (3), the results of "Basis of  $\beta$ -smooth only" were based on the smoothing  $\beta_{\ell}(t)$  only approach of model (5), the results of "Additive model (7)" were based on the additive effect model (7), and the *P*-values of Hom-MetaSKAT and Hom-MetaSKAT-O were based on the R package MetaSKAT. GVF, genetic variant function.

and one from Germany (DIAGEN). The two Norwegian cohorts are combined as one study for a joint analysis. The genotype data were from Metabochip genotyping, which was designed to fine map regions that have been associated to metabolic traits (Altshuler *et al.* 2010). For each cohort, 54,741 genetic variants were genotyped.

For our analysis, we utilized the existing literature as a reference for gene selection and found that 22 gene regions were fine mapped (Liu *et al.* 2014). We used Builder Mar. 2006 (NCBI36/hg18) to determine gene positions and 5 kb was used to extend the gene region on each side of a gene. The summary of 22 genes and the number of genetic variants in each gene region are given in Supporting Information, Table S1.

Four lipid traits were analyzed: high-density lipoprotein (HDL) levels, low-density lipoprotein (LDL) levels, triglycerides (TG), and total cholesterol (CHOL). The sample sizes for each trait are provided in Table S2. For each trait, inverse normal rank transformation was performed to make sure that normality is valid. For all studies except for METSIM, age, sex, and type 2 diabetes status were used as covariates. For METSIM, age and type 2 diabetes status were used as covariates since no female was included in the study. A significance threshold of  $P < 3.1 \times 10^{-6}$  was taken from Liu *et al.* (2014) (corresponding to 0.05/16,153 and allowing for the number of genes tested therein). In addition, a covariate for Norwegian study origin was created, since the two Norwegian cohorts were analyzed jointly.

Table 1 reports results of association analysis of the eight European cohorts by homogeneous LRT (Hom-LRT), Hom-MetaSKAT-O, and Hom-MetaSKAT; and Table 2 reports results by heterogeneous LRT (Het-LRT), Het-MetaSKAT-O, and Het-MetaSKAT. The results of Hom-F and Het-F are reported in Table S3 and Table S4. At the significance threshold of  $P < 3.1 \times 10^{-6}$ , we observe the following associations by both Hom-LRT and Hom-F of functional regression models (3) and (5): (1) at the *LPL* for HDL levels; (2) at the *APOB*, *APOE*, *LDLR*, and *PCSK9* for LDL levels; (3) at the *APOE* and *LPL* for TG levels; and (4) at the *APOB*, *APOE*, *HNF1A*, and *LDLR* for CHOL levels. Hom-MetaSKAT and Hom-MetaSKAT-O detect the following associations: (1) at the *APOE*, *LDLR*, and *PCSK9* for LDL levels and (2) at the *APOE* and *LDLR* for CHOL levels.

By both Het-LRT and Het-F of functional regression models (3) and (5) shown in Table 2 and Table S4, we observe the following associations: (1) at the *APOB*, *APOE*, *CDC123*, *CDKAL1*, *CDKN2B*, *FTO*, *HNF1A*, *LDLR*, *OASL*, *PCSK9*, and *TSPAN8* for LDL levels; (2) at the *LPL* for TG levels; and (3) at the *APOB*, *APOE*, *CDC123*, *CDKAL1*, *CDKN2B*, *FTO*, *HNF1A*, *IDE*, *JAZF1*, *KIF11*, *LDLR*, *MTNR1B*, *OASL*, *PCSK9*, and *TSPAN8* for CHOL levels. Het-MetaSKAT and Het-MetaSKAT-O detect the following associations: (1) at the *APOE* and *LDLR* for LDL levels and (2) at the *APOE* for CHOL levels.

In addition to the results of functional regression models (3) and (5), MetaSKAT, and MetaSKAT-O, Table 1, Table 2, Table S3, and Table S4 report the results of the traditional additive effect models (6) and (7). The additive effect models (6) and (7) detect more association signals than Meta-SKAT and MetaSKAT-O, but less than the functional regression models (3) and (5).

Generally, the *P*-values of Hom-LRT in Table 1 are slightly smaller than those of Hom-F in Table S3, and the *P*-values of Het-LRT in Table 2 are slightly smaller than those of Het-F in Table S4. Hence, the LRT statistics are slightly more powerful than the *F*-distributed statistics. In addition, Het-LRT and Het-F detect more association signals than Hom-LRT and Hom-F. Overall, the *P*-values of Hom-MetaSKAT-O and Hom-MetaSKAT are bigger than those of Hom-LRT and

			Р	-values of the He	et-LRT			
		Basis of both	GVF and $eta_\ell(t)$	Basis of $\beta$ -s	mooth only		P-values of	Het-Meta-
Traits	Gene	B-spline basis	Fourier basis	B-spline basis	Fourier basis	Additive model (6)	SKAT	SKAT-O
LDL	APOB	$5.05 imes10^{-11}$	$4.72\times10^{-8}$	$5.05 imes10^{-11}$	$4.72  imes 10^{-8}$	3.37 × 10 <sup>-6</sup>	$7.61 \times 10^{-2}$	$1.40 \times 10^{-1}$
	APOE	$1.59 \times 10^{-81}$	$1.11 imes10^{-79}$	$1.59 \times 10^{-81}$	$1.11  imes 10^{-79}$	$7.47 imes10^{-79}$	$2.23 imes10^{-33}$	$1.28 imes10^{-38}$
	CDC123	$1.72 imes10^{-6}$	$3.19 \times 10^{-8}$	$1.72 imes10^{-6}$	$3.19 \times 10^{-8}$	$5.04 \times 10^{-3}$	$2.54  imes 10^{-1}$	$4.19 \times 10^{-1}$
	CDKAL1	$5.06 imes10^{-7}$	$4.78 imes10^{-8}$	$5.06 imes10^{-7}$	$4.78 imes10^{-8}$	$6.41  imes 10^{-3}$	$3.74  imes 10^{-1}$	$5.81  imes 10^{-1}$
	CDKN2B	$6.64  imes 10^{-7}$	$9.82  imes 10^{-6}$	$6.64  imes 10^{-7}$	$1.20 \times 10^{-5}$	$1.51 \times 10^{-5}$	$7.46  imes 10^{-1}$	$9.20 \times 10^{-1}$
	FTO	$2.08 imes10^{-6}$	$1.05  imes 10^{-5}$	$2.08 imes10^{-6}$	$1.05  imes 10^{-5}$	$3.32  imes 10^{-4}$	$1.11 \times 10^{-2}$	$2.23 \times 10^{-2}$
	HNF1A	$6.22  imes 10^{-11}$	$5.41 imes10^{-8}$	$6.22  imes 10^{-11}$	$2.26 imes10^{-8}$	$8.07  imes 10^{-11}$	$1.31  imes 10^{-1}$	$2.26  imes 10^{-1}$
	LDLR	$6.09  imes 10^{-9}$	$1.40 imes10^{-9}$	$8.61  imes 10^{-9}$	$1.23 \times 10^{-9}$	$2.29  imes \mathbf{10^{-9}}$	$4.27  imes 10^{-7}$	$4.93  imes 10^{-7}$
	OASL	$1.13 imes10^{-7}$	$4.17  imes 10^{-6}$	$1.13 imes10^{-7}$	$5.98  imes 10^{-6}$	$8.06  imes 10^{-6}$	$1.20  imes 10^{-1}$	$8.81  imes 10^{-2}$
	PCSK9	$4.95 imes10^{-9}$	$\pmb{8.98\times10^{-13}}$	$4.95 imes10^{-9}$	$2.01  imes 10^{-11}$	$4.54  imes 10^{-12}$	$9.03  imes 10^{-4}$	$2.09 \times 10^{-3}$
	TSPAN8	$6.94 \times 10^{-9}$	$1.63\times10^{-10}$	$7.94 imes10^{-11}$	$1.03 \times 10^{-10}$	$1.63 imes10^{-10}$	$6.47  imes 10^{-2}$	$1.22 \times 10^{-1}$
TG	LPL	$1.26  imes 10^{-5}$	$8.50 imes10^{-7}$	$1.26  imes 10^{-5}$	$8.50 \times 10^{-7}$	$4.44 \times 10^{-5}$	$3.38 \times 10^{-6}$	$6.30  imes 10^{-6}$
CHOL	APOB	$1.38 \times 10^{-12}$	$3.37  imes 10^{-10}$	$1.38  imes 10^{-12}$	$3.37  imes 10^{-10}$	$1.15 imes10^{-9}$	$6.04  imes 10^{-2}$	$1.12 \times 10^{-1}$
	APOE	$2.47  imes 10^{-55}$	$1.36 \times 10^{-52}$	$2.47  imes 10^{-55}$	$1.36  imes 10^{-52}$	$1.60 imes10^{-52}$	$2.76  imes 10^{-20}$	$3.08 imes10^{-22}$
	CDC123	$2.29 imes10^{-6}$	$1.40 imes10^{-6}$	$2.29 imes10^{-6}$	$1.40 imes10^{-6}$	$1.03 \times 10^{-2}$	$7.13  imes 10^{-1}$	$8.97  imes 10^{-1}$
	CDKAL1	$4.62  imes 10^{-8}$	$2.70 \times 10^{-9}$	$4.62  imes 10^{-8}$	$2.70 imes10^{-9}$	$1.11 \times 10^{-4}$	$1.17  imes 10^{-1}$	$2.06 \times 10^{-1}$
	CDKN2B	$1.82 imes10^{-7}$	$1.36 imes10^{-6}$	$1.82 imes10^{-7}$	$6.38 imes10^{-7}$	$1.20 imes10^{-6}$	$1.17  imes 10^{-1}$	$6.39  imes 10^{-1}$
	FTO	$2.85  imes 10^{-7}$	$1.48 imes10^{-6}$	$2.85 imes10^{-7}$	$1.48 imes10^{-6}$	$5.37 imes10^{-7}$	$9.84  imes 10^{-3}$	$1.99  imes 10^{-2}$
	HNF1A	$4.32 imes10^{-11}$	$8.98 imes10^{-9}$	$4.32 imes10^{-11}$	$8.31  imes 10^{-9}$	$3.64 imes10^{-10}$	$4.33  imes 10^{-1}$	$5.38  imes 10^{-1}$
	IDE	$6.12  imes 10^{-5}$	$1.37 imes10^{-6}$	$6.12  imes 10^{-5}$	$1.37 imes10^{-6}$	$7.52  imes 10^{-5}$	$2.30  imes 10^{-1}$	$3.86  imes 10^{-1}$
	JAZF1	$2.20  imes 10^{-6}$	$3.95  imes 10^{-6}$	$2.20  imes 10^{-6}$	$3.95  imes 10^{-6}$	$6.89  imes 10^{-4}$	$9.52  imes 10^{-2}$	$1.71  imes 10^{-1}$
	KIF11	$9.75  imes 10^{-7}$	$6.69  imes 10^{-7}$	$9.75 imes10^{-7}$	$6.69  imes 10^{-7}$	$1.26 \times 10^{-5}$	$2.77  imes 10^{-1}$	$4.40  imes 10^{-1}$
	LDLR	$2.42 imes10^{-6}$	$3.91 \times 10^{-8}$	$3.22  imes 10^{-6}$	$3.73 imes10^{-8}$	$7.15 imes10^{-8}$	$4.77 \times 10^{-4}$	$2.28  imes 10^{-5}$
	MTNR1B	$6.80  imes 10^{-7}$	$5.91 imes10^{-7}$	$6.80 imes10^{-7}$	$1.34 imes10^{-7}$	$5.71 imes10^{-7}$	$4.16  imes 10^{-2}$	$7.48  imes 10^{-2}$
	OASL	$1.11  imes 10^{-7}$	$9.27  imes 10^{-8}$	$1.11  imes 10^{-7}$	$1.42  imes 10^{-7}$	$9.66 imes10^{-8}$	$3.11  imes 10^{-1}$	$5.06  imes 10^{-2}$
	PCSK9	$1.87  imes 10^{-5}$	$2.09 imes10^{-6}$	$1.87  imes 10^{-5}$	$8.17  imes 10^{-6}$	$5.45 imes10^{-7}$	$1.89  imes 10^{-2}$	$3.72 \times 10^{-2}$
	TSPAN8	$1.11\times10^{-10}$	$2.29\times\mathbf{10^{-13}}$	$3.15 \times 10^{-13}$	$2.89\times\mathbf{10^{-13}}$	$2.70\times\mathbf{10^{-13}}$	$9.43  imes 10^{-2}$	$1.74 \times 10^{-1}$

Table 2 Association analysis of lipid traits in eight European cohorts by heterogeneous likelihood-ratio tests (Het-LRT), Het-MetaSKAT-O, and Het-MetaSKAT

The associations that attain a threshold significance of  $P < 3.1 \times 10^{-6}$  are boldface (Liu *et al.* 2014). The results of "Basis of both GVF and  $\beta_{\ell}(t)$ " were based on smoothing both GVF and genetic effect functions  $\beta_{\ell}(t)$  of model (3), the results of "Basis of  $\beta$ -smooth only" were based on the smoothing  $\beta_{\ell}(t)$  only approach of model (5), the results of "Additive model (6)" were based on the additive effect model (6), and the *P*-values of Het-MetaSKAT and Het-MetaSKAT-O were based on the R package MetaSKAT. GVF, genetic variant function.

Hom-F, and the *P*-values of Het-MetaSKAT-O and Het-MetaSKAT are bigger than those of Het-LRT and Het-F. Therefore, MetaSKAT is less sensitive than the proposed LRT and *F*-distributed statistics.

When we analyze the data sets separately for each study, significant association is detected only at *APOE* for LDL and CHOL, levels for a few studies and at *LDLR* for CHOL levels in the study of METSIM (Table S5). No significant association is detected for TG and HDL levels in any separate study. The *P*-values of separate analysis in Table S5 are much bigger than those of meta-analysis in Table 1, Table 2, Table S3, and Table S4. Thus, it is more advantageous to perform meta-analysis of multiple studies.

#### A simulation study

To evaluate the performance of the proposed methods, we carried out simulation analyses for two cases: (1) the causal variants are all rare and (2) the causal variants are both rare and common. Simulations were performed for three scenarios listed in Table 3 (Lee *et al.* 2013). For scenarios 1 and 2, we used the European-like (EUR) sequence data used in Lee *et al.* (2012). For scenario 3, we used both the EUR and

African–American-like (AA) sequence data. Specifically, the EUR sequence data were generated using COSI's (available at: http://www.broadinstitute.org/~sfs/) calibrated best-fit models, and the generated European haplotypes mimick Centre d'Etude du Polymorphisme Humain (CEPH) Utah individuals with ancestry from northern and western Europe in terms of site frequency spectrum and LD pattern (figure 4 in Schaffner et al. 2005; International HapMap Consortium 2007). Similarly, the AA sequence data mimick individuals with a 20:80 mixture of Europeans and Africans, together with parameters calibrated to model realistic demographic history (including bottleneck, population expansion, and migration events). The EUR sequence data included 10,000 chromosomes covering 1-Mb regions, and the AA sequence data included 45,000 chromosomes covering 0.1-Mb regions. Genetic regions of 3-kb length were randomly selected in the simulations for type I error and power calculations.

*Type I error simulations:* To evaluate the type I error rates of the proposed models and tests, we generated phenotype data sets by using the model

Table 3	Simulation	study	settings
---------	------------	-------	----------

			Sample sizes			Covariates	
Scenario	Population	Study 1	Study 2	Study 3	Study 1	Study 2	Study 3
1	EUR	1600	2200	3200	$(z_1, z_2)$	$(z_1, z_2)$	$(z_1, z_2)$
2	EUR	1600	2200	3200	<i>Z</i> <sub>1</sub>	$(z_1, z_2)$	$(z_1, z_2, z_3)$
3	EUR + AA	1600	2200	3200	<i>Z</i> <sub>1</sub>	$(z_1, z_2)$	$(z_1, z_2, z_3)$

Sample sizes are total sample sizes in each study. Covariates represent covariates in each study. EUR refers to the scenario where all three studies had EUR samples. EUR + AA refers to the scenario where studies 1 and 2 had EUR samples and study 3 had AA samples.  $z_1$  is a binary covariate taking values 0 and 1 each with probability 0.5, and  $z_2$  and  $z_3$  are continuous covariates and distributed as standard normal.

$$y_{\ell i} = 0.5 z_{\ell i 1} + 0.5 z_{\ell i 2} + \varepsilon_{\ell i}, \quad \ell = 1, 2, 3,$$
 (8)

for scenario 1 in Table 3 and

$$y_{1i} = 0.5z_{1i1} + \varepsilon_{1i}$$
  

$$y_{2i} = 0.5z_{2i1} + 0.5z_{2i2} + \varepsilon_{2i}$$
  

$$y_{3i} = 0.5z_{3i1} + 0.5z_{3i2} + 0.5z_{3i3} + \varepsilon_{3i}$$
(9)

for scenarios 2 and 3 in Table 3, where  $z_{\ell i1}$  is a dichotomous covariate taking values 0 and 1 with an equal probability of 0.5,  $z_{\ell i2}$  and  $z_{\ell i3}$  are continuous covariates from standard normal distributions N(0, 1), and  $\epsilon_{\ell i}$  follows a standard normal distribution N(0, 1). To obtain genotype data, 3-kb subregions were randomly selected in the 1-Mb region of EUR-like data and the 0.1-Mb region of AA-like data. The ordered genotypes were these SNPs in the 3-kb subregions. Note that the trait values are not related to the genotypes, and so the null hypothesis holds. The sample sizes of the data sets were taken as 1600 (study 1), 2200 (study 2), and 3200 (study 3), respectively. The simulation settings are summarized in Table 3. For each sample size combination, 106 phenotype-genotype data sets were generated to fit the proposed models and to calculate the test statistics and related P-values. Then, an empirical type I error rate was calculated as the proportion of 10<sup>6</sup> P-values that were smaller than a given  $\alpha$ -level (*i.e.*, 0.05, 0.01 and 0.001, 0.0001, respectively).

*Empirical power simulations:* To evaluate the power performance of the proposed tests, we simulated data sets under the alternative hypothesis by randomly selecting 3-kb subregions to obtain causal variants for the phenotype values as follows. Once a 3-kb subregion was selected, a subset of p causal variants located in the 3-kb subregion was then randomly selected to obtain ordered genotypes  $(g(t_1), \dots, g(t_p))$ . Then, we generated the quantitative traits by

$$egin{aligned} &y_{\ell i}=0.5 z_{\ell i 1}+0.5 z_{\ell i 2}+eta_{\ell i 1} g(t_1)+\cdots+eta_{\ell i p} gig(t_pig)+arepsilon_{\ell i},\ &\ell=1,2,3, \end{aligned}$$

for scenario 1 and for scenarios 2 and 3,

$$\begin{split} y_{1i} &= 0.5 z_{1i1} + \beta_{1i1} g(t_1) + \dots + \beta_{1ip} g(t_p) + \varepsilon_{1i} \\ y_{2i} &= 0.5 z_{2i1} + 0.5 z_{2i2} + \beta_{2i1} g(t_1) + \dots + \beta_{2ip} g(t_p) + \varepsilon_{2i} \\ y_{3i} &= 0.5 z_{3i1} + 0.5 z_{3i2} + 0.5 z_{3i3} \\ &+ \beta_{3i1} g(t_1) + \dots + \beta_{3ip} g(t_p) + \varepsilon_{3i}, \end{split}$$

where  $z_{\ell i j}$  and  $\varepsilon_{\ell i}$  are the same as in the type I error models (8) and (9), and the  $\beta$ 's are the additive effect for the causal variants defined as follows. We used  $|\beta_{\ell i i}| = c_{\ell} |\log_{10}(MAF_i)|/2$ , where MAF<sub>i</sub> was the minor allele frequency (MAF) of the jth variant. Three genetic effect scenarios were used to perform power calculations: (1) all causal variants had positive effects, (2) 20%/80% causal variants had negative/positive effects, and (3) 50%/50% causal variants had negative/positive effects. As in Lee et al. (2013), four different settings were considered: 5%, 10%, 20%, and 50% of variants in the 3-kb subregion are chosen as causal variants. When 5%, 10%, 20%, and 50% of the variants were causal, two parameter settings of genetic effects were considered for  $c_{\ell}$ : (1) homogeneous and (2) heterogeneous (Table 4). In the homogeneous case, the genetic effects are the same for the three studies; i.e.,  $c_1 = c_2 = c_3$ . In the heterogeneous case, the genetic effects are different for the three studies; *i.e.*,  $c_2 = c_1 + 0.15$ ,  $c_3 = c_1 - 0.15$ . For each setting, 1000 data sets were simulated to calculate the empirical power as the proportion of *P*-values that are smaller than a given  $\alpha = 0.0001$  level. The homogeneous settings of genetic effect are taken from Lee et al. (2013).

Type I error simulation results: The empirical type I error rates are reported in Table 5 when the causal variants are only rare and in Table 6 when the causal variants are both rare and common. For each entry of empirical type I error rates, we generated 10<sup>6</sup> data sets. Results of four different  $\alpha = 0.05, \ 0.01, \ 0.001,$  and 0.0001 levels are reported. For both the proposed F-distributed tests and LRT statistics of the functional linear models, all empirical type I error rates are around the nominal  $\alpha$ -levels for both B-spline basis and Fourier basis (columns 4-11 of Table 5 and Table 6). Therefore, both the F-distributed tests and LRT statistics of the functional linear models controlled type I error rates correctly for all scenarios at all significance levels. The functional linear models and related F-distributed tests and LRT statistics can be useful in both whole-genome and wholeexome association studies.

*Statistical power results:* We compared the power performance of the proposed tests with MetaSKAT and MetaBurden tests based on the simulated COSI sequence data. The empirical power levels of the proposed LRT statistics at the

			Caus	al %	
Genetic effect	Study $(c_{\ell})$	5	10	20	50
Homogeneous	1 (c <sub>1</sub> )	0.475	0.375	0.25	0.175
-	$2(c_2)$	0.475	0.375	0.25	0.175
	3 (c <sub>3</sub> )	0.475	0.375	0.25	0.175
Heterogeneous	1 (c <sub>1</sub> )	0.475	0.375	0.25	0.175
-	$2(c_2)$	0.475 + 0.15	0.375 + 0.15	0.25 + 0.15	0.175 + 0.15
	3 (C <sub>3</sub> )	0.475 - 0.15	0.375 - 0.15	0.25 - 0.15	0.175 – 0.15

The constants  $c_\ell$  in  $\beta_\ell = c_\ell |\log_{10}(MAF)|/2$  of power simulations,  $\ell = 1, 2, 3$ , are given for two cases: (1) homogeneous genetic effect and (2) heterogeneous genetic effect.

 $\alpha = 0.0001$  level are plotted in Figure 1, Figure 2, Figure 3, Figure 4, Figure S1, Figure S2, Figure S3, and Figure S4. In the legends of all the figures, "GVF&Beta, B-sp" (or "GVF&Beta, F-sp") means that both genetic variant function and genetic effect function  $\beta(t)$  were smoothed by B-spline (or Fourier) basis functions, and "Beta, B-sp" (or "Beta, F-sp") means that only the genetic effect function  $\beta(t)$  was smoothed by B-spline (or Fourier) basis functions (*i.e.*,  $\beta$ -smooth only). Moreover, the results of "Het-MetaSKAT," "Het-MetaSKAT-O," "Hom-MetaSKAT," "Hom-MetaSKAT-O," and the metaburden weighted sum test (MetaBurdenWST) using the R package MetaSKAT are reported for power comparison (Madsen and Browning 2009; Lee *et al.* 2012, 2013).

In Figure 1, Figure 2, Figure 3, and Figure 4, the results of "Hom-LRT" are reported, where the LRT statistics are constructed using the homogeneous effect model that assumes  $\beta_1 = \beta_2 = \beta_3$ . In Figure S1, Figure S2, Figure S3, and Figure S4, the results of "Het-LRT" are reported, where the LRT statistics are constructed using the heterogeneous effect model in which the regression coefficients  $\beta_1, \beta_2$ , and  $\beta_3$  are different from each other. In Figure 1, Figure 2, Figure S1, and Figure S2, the simulated data are generated under the assumption of homogeneous genetic effect; and in Figure 3, Figure 4, Figure S3, and Figure S4, the simulation data are generated under the assumption of heterogeneous genetic effect (Table 4).

The proposed homogeneous LRT statistics (Hom-LRT) of the functional linear models have higher power than that of MetaSKAT and MetaSKAT-O in Figure 1, Figure 2, Figure 3, and Figure 4. The heterogeneous LRT statistics (Het-LRT) of the functional linear models also have higher power than that of MetaSKAT and MetaSKAT-O in Figure S1, Figure S2, Figure S3, and Figure S4, except for a few cases in Figure S2 when 20% or 50% of variants were causal. Therefore, the proposed LRT statistics of the functional linear models have superior performance in most cases. In Figure S2, the simulated data were generated using the homogeneous genetic effect (Table 4), but the data were analyzed by the heterogeneous effect model and the test is Het-LRT. Thus, it is not strange that there is power loss by Het-LRT in Figure S2.

As shown in Lee *et al.* (2013, p. 44), MetaSKAT-O takes the minimum *P*-value of a weighted average of MetaSKAT and the metaburden weighted sum test for a range of  $\rho$ values over [0, 1] and the metaburden weighted sum test corresponds to  $\rho = 1$  in the construction of SKAT-O. Therefore, the power of MetaBurdenWST is generally lower than that of MetaSKAT-O. This is consistent with the results of Lee *et al.* (2013).

In Figure 1 and Figure 2, the simulated data were generated under the assumption of homogeneous genetic effect and the data were analyzed by the homogeneous effect model and the test was Hom-LRT. In Figure S3 and Figure S4, the simulated data were generated under the assumption of heterogeneous genetic effect and the data were analyzed by the heterogeneous effect model and the test was Het-LRT. Therefore, "correct models" were used in analyzing the simulated data in Figure 1, Figure 2, Figure S3, and Figure S4, in which the proposed LRT statistics have significantly higher power levels than those of MetaSKAT. Even when "wrong models" were used to analyze the simulated data in Figure 3, Figure 4, Figure S1, and Figure S2, the empirical power levels of the proposed LRT statistics were much higher than those of MetaSKAT in most cases except a few in Figure S2.

In total, we compared four LRT statistics of the functional linear models in each graph: two are based on B-spline basis functions, and two are based on Fourier basis functions. In the two LRT statistics to use B-spline (or Fourier) basis functions, one is to smooth both the genetic variant functions and the genetic effect function  $\beta(t)$ , and the other is to smooth only the genetic effect function  $\beta(t)$  (*i.e.*,  $\beta$ -smooth only). Generally, the four LRT statistics of the functional linear models have similar power. The power levels of  $\beta$ -smooth only are almost identical to those of smoothing both the genetic variant functions and the genetic variant functions and the genetic effect function  $\beta(t)$  by B-spline basis (or Fourier basis). Thus, the tests do not strongly depend on whether the genotype data are smoothed or not. In addition, the LRT statistics do not strongly depend on which basis functions are used.

In addition to the LRT statistics, we calculated the empirical power levels of the F-distributed statistics, which provide very similar empirical power levels as the LRT statistics (data not shown).

#### Discussion

In this article, FLMs are developed to perform gene-level meta-analysis of quantitative traits for a combined analysis

				F-distributed	statistics			LRT stati	stics	
			Basis of both	GVF and $\beta_{\ell}(t)$	Basis of $\beta$ -s	mooth only	Basis of both	GVF and $\beta_{\ell}(t)$	Basis of $\beta$ -s	mooth only
Type of tests	Scenario	Level $\alpha$	B-spline	Fourier	B-spline	Fourier	B-spline	Fourier	B-spline	Fourier
Het-F and Het-LRT	1	0.05 0.01 0.001 0.0001	0.049876 0.009932 0.000991 0.000089	0.049922 0.010006 0.000974 0.000097	0.050093 0.009987 0.001000 0.000091	0.049924 0.010029 0.000971 0.000095	0.050611 0.010173 0.001055 0.000094	0.050895 0.010407 0.001056 0.000107	0.050819 0.010225 0.001065 0.000097	0.050916 0.010422 0.001056 0.000105
	2	0.05 0.01 0.001 0.0001	0.049838 0.009944 0.001024 0.000094	0.050189 0.009848 0.001021 0.000101	0.050077 0.009998 0.001036 0.000094	0.050194 0.009851 0.001025 0.000102	0.050546 0.010239 0.001079 0.000103	0.051163 0.010251 0.001082 0.000118	0.050789 0.010305 0.001090 0.000105	0.051164 0.010253 0.001088 0.000118
	3	0.05 0.01 0.001 0.0001	0.049886 0.009948 0.000981 0.000106	0.050002 0.010084 0.001044 0.000093	0.050081 0.009989 0.000985 0.000108	0.049940 0.010090 0.001035 0.000097	0.050593 0.010255 0.001029 0.000116	0.050934 0.010454 0.001104 0.000105	0.050789 0.010294 0.001033 0.000118	0.050906 0.010446 0.001098 0.000108
Hom-F and Hom-LRT	1	0.05 0.01 0.001 0.0001	0.049834 0.009932 0.000987 0.000091	0.049795 0.009901 0.001039 0.000102	0.049948 0.009896 0.001030 0.000077	0.049906 0.010018 0.000996 0.000108	0.050131 0.010050 0.001000 0.000098	0.050221 0.010062 0.001070 0.000104	0.050240 0.010012 0.001054 0.000078	0.050337 0.010216 0.001022 0.000112
	2	0.05 0.01 0.001 0.0001	0.050140 0.009995 0.000965 0.000095	0.050340 0.010131 0.001029 0.000106	0.050057 0.010001 0.000977 0.000085	0.050050 0.009911 0.000998 0.000092	0.050459 0.010103 0.000984 0.000099	0.050784 0.010308 0.001061 0.000111	0.050349 0.010141 0.001001 0.000088	0.050475 0.010078 0.001031 0.000097
	3	0.05 0.01 0.001 0.0001	0.049900 0.010043 0.001025 0.000090	0.049757 0.010068 0.001002 0.000121	0.050173 0.010047 0.001010 0.000098	0.049742 0.009950 0.001017 0.000118	0.050201 0.010157 0.001045 0.000092	0.050213 0.010260 0.001023 0.000128	0.050453 0.010161 0.001035 0.000100	0.050180 0.010138 0.001060 0.000125

Table 5 Empirical type I error rates of *F*-distributed statistics and LRT statistics at different  $\alpha$ -levels based on 10<sup>6</sup> simulated data sets, when the causal variants are only rare

The results of "Basis of both GVF and  $\beta_{\ell}(t)$ " were based on smoothing both GVF and genetic effect functions  $\beta_{\ell}(t)$  of model (3), and the results of "Basis of  $\beta$ -smooth only" were based on the smoothing  $\beta_{\ell}(t)$  only approach of model (5). GVF, genetic variant function.

of multiple studies. By using functional data analysis techniques, the theoretical FLMs (1) and (4) are transformed to be traditional multiple linear regressions (3) and (5) (de Boor 2001; Ramsay and Silverman 2005; Ramsay et al. 2009; Ferraty and Romain 2010; Horváth and Kokoszka 2012). The null hypothesis of association is tested by LRT and F-distributed statistics. We show that the proposed LRT and F-distributed statistics control the type I error very well and have higher empirical power levels than the existing methods such as MetaSKAT and MetaBurdenWST in most simulations. By applying the proposed methods to analyze four blood lipid levels in data from a meta-analysis of eight European studies, it is found that the proposed methods detect more significant association than MetaSKAT and MetaSKAT-O, and the P-values of the proposed LRT and Fdistributed statistics are usually much smaller than those of MetaSKAT and MetaSKAT-O.

One reason that the proposed functional linear models perform better is that SKAT and MetaSKAT do not model LD among genetic markers sufficiently. Specifically, the test statistic of SKAT is given by  $Q_s = (\mathbf{y} - \hat{\pi})' GWWG'(\mathbf{y} - \hat{\pi}) = \sum_{j=1}^{m} w_j^2 \{\sum_{i=1}^{n} g_{ij}(y_i - \hat{\pi}_i)\}^2$ , where  $\mathbf{y} = (y_1, \dots, y_n)'$  is the trait value column vector,  $G = (G_1, \dots, G_n)'$  is the  $n \times m$  genotype matrix, and W =

diag $(w_1, \dots, w_m)$  is an  $m \times m$  diagonal weight matrix using the notations of Lee *et al.* (2012). Let  $S_j = \sum_{i=1}^n g_{ij}(y_i - \hat{\pi}_i)$ . Then,  $S_j$  is the score test statistic for testing  $H_0 : \beta_j = 0$  in the single genetic variant model with only the *j*th genetic variant

$$\operatorname{logit}(\pi_i) = \alpha_0 + Z'\alpha + g_{ij}\beta_j.$$

Thus,  $S_j$  models the pairwise LD between the *j*th genetic variant and the trait locus. Note that  $Q_S = \sum_{j=1}^m w_j^2 S_j^2$  is a weighted summation of the squared score test statistics  $S_j$ . Therefore, the test statistics of SKAT and MetaSKAT model pairwise LD only between each individual marker and the trait locus, while the LD among genetic markers are not modeled.

Note that Lee *et al.* (2012) used dichotomous traits to present the test statistic  $Q_s$ , but the formulation of  $Q_s$  is also the same for continuous traits or survival traits (Chen *et al.* 2014). SKAT and MetaSKAT were constructed as score tests on the variance component parameter for the genetic random variations in linear or logistic mixed-effects models. The reason that the regression coefficients of genetic terms were assumed to be random in the models of SKAT and MetaSKAT is that the number of genetic variants in a genetic

				F-distributed	statistics			LRT stati	stics	
			Basis of both	GVF and $\beta_{\ell}(t)$	Basis of $\beta$ -s	mooth only	Basis of both	GVF and $\beta_{\ell}(t)$	Basis of $\beta$ -s	mooth only
Type of tests	Scenari	o Level $\alpha$	B-spline	Fourier	B-spline	Fourier	B-spline	Fourier	B-spline	Fourier
Het-F and Het-LRT	1	0.05 0.01 0.001 0.0001	0.050146 0.009964 0.000993 0.000108	0.049931 0.009942 0.000996 0.000088	0.050220 0.009983 0.000997 0.000109	0.049953 0.009945 0.000996 0.000088	0.050853 0.010250 0.001057 0.000116	0.050913 0.010303 0.001078 0.000097	0.050928 0.010268 0.001061 0.000117	0.050936 0.010308 0.001078 0.000097
	2	0.05 0.01 0.001 0.0001	0.049942 0.009974 0.000960 0.000079	0.050298 0.009993 0.000970 0.000092	0.050014 0.010001 0.000967 0.000080	0.050324 0.010001 0.000970 0.000093	0.050705 0.010268 0.001013 0.000089	0.051303 0.010396 0.001046 0.000099	0.050786 0.010291 0.001017 0.000090	0.051330 0.010402 0.001046 0.000099
	3	0.05 0.01 0.001 0.0001	0.050100 0.010060 0.000989 0.000109	0.050012 0.010008 0.001022 0.000099	0.050159 0.010089 0.000989 0.000111	0.050008 0.010010 0.001021 0.000099	0.050844 0.010328 0.001032 0.000117	0.051006 0.010367 0.001098 0.000111	0.050911 0.010360 0.001034 0.000118	0.051000 0.010375 0.001096 0.000110
Hom-F and Hom-LRT	1	0.05 0.01 0.001 0.0001	0.049899 0.010127 0.001004 0.000084	0.049875 0.010135 0.001031 0.000113	0.050077 0.010014 0.001007 0.000092	0.050165 0.010043 0.001001 0.000085	0.050193 0.010225 0.001017 0.000087	0.050331 0.010309 0.001050 0.000119	0.050374 0.010135 0.001027 0.000095	0.050595 0.010230 0.001047 0.000089
	2	0.05 0.01 0.001 0.0001	0.049982 0.010037 0.001025 0.000108	0.050054 0.010105 0.001019 0.000101	0.050017 0.009901 0.000993 0.000098	0.049746 0.009977 0.000982 0.000096	0.050267 0.010170 0.001048 0.000111	0.050461 0.010280 0.001056 0.000109	0.050289 0.010020 0.001016 0.000104	0.050168 0.010157 0.001018 0.000101
	3	0.05 0.01 0.001 0.0001	0.050401 0.009975 0.000993 0.000116	0.049749 0.009920 0.000993 0.000100	0.050276 0.010148 0.000966 0.000097	0.050243 0.009904 0.000997 0.000089	0.050693 0.010097 0.001019 0.000119	0.050187 0.010082 0.001039 0.000108	0.050551 0.010272 0.000995 0.000097	0.050694 0.010088 0.001037 0.000093

Table 6 Empirical type I error rates of *F*-distributed statistics and LRT statistics at different  $\alpha$ -levels based on 10<sup>6</sup> simulated data sets, when the causal variants are both rare and common

The results of "Basis of both GVF and  $\beta_{\ell}(t)$ " were based on smoothing both GVF and genetic effect functions  $\beta_{\ell}(t)$  of model (3), and the results of "Basis of  $\beta$ -smooth only" were based on the smoothing  $\beta_{\ell}(t)$  only approach of model (5). GVF, genetic variant function.

region is usually large. For instance, there are 660 genetic variants in the region of the *KCNQ1* gene in data of European cohorts, Table S1. Due to a large number of genetic terms in a regression model, it is hard to estimate the genetic effects of all genetic variants by ordinary fixed-effect regression models. By making the regression coefficients of the genetic terms to be random, the theory of mixed models was used to build the test statistics of SKAT and MetaSKAT (Lee *et al.* 2012, 2013).

In association studies, association between phenotypic traits and major gene loci is tested. If the number of causal genetic variants at a major gene locus is very large and each causal variant makes a small contribution to the phenotype, the assumption of mixed models will be satisfied and SKAT and MetaSKAT should perform well (Fisher 1918). On the other hand, if the number of causal genetic variants at a major gene locus is not large and the contribution of a few causal variants to the phenotype is reasonably large, fixedeffect models should work well. In our simulation studies and real data analysis, the proposed functional linear models perform better than SKAT and MetaSKAT in most cases. Thus, the mixed models of SKAT and MetaSKAT could be statistically convenient and attractive but not necessarily biologically reasonable. We argue that the fixed-effect models are useful in most cases. In practice, it makes sense to perform analysis by both the fixed- and mixed-effect models and make a comparison, and this can be readily done using our R codes and SKAT and MetaSKAT packages.

The proposed FLMs are fixed-effect models that can analyze large numbers of genetic variants and extend traditional population genetics models naturally. Unlike other methods such as SKAT or MetaSKAT and burden tests that treat genetic variants as discrete variables, FLMs treat the genetic variant data as continuous stochastic functions or realizations of an underlying stochastic process (Ross 1996). Since genetic variant data are treated as functions, the genetic effects are modeled as functions. One advantage of treating genetic variant data as functions is that the LD information and genetic positions of genetic variant data are contained in the genetic variant functions. The regression coefficients of genetic terms in the models of SKAT and MetaSKAT do not depend on the genetic position, while our genetic effect function depends on the genetic position and is actually a function of genetic position. Hence, the proposed models can fully utilize LD and genetic position information.



**Figure 1** The empirical power of the homogeneous LRT statistics (Hom-LRT) of models (3) and (5), MetaSKAT, and MetaBurdenWST at  $\alpha = 0.0001$ , when causal variants were both rare and common and the genetic effect is simulated as homogeneous. When Neg pct = 0, all causal variants had positive effects; when Neg pct = 20, 20%/80% of causal variants had negative/positive effects; when Neg pct = 50, 50%/50% of causal variants had negative/positive effects.



**Figure 2** The empirical power of the homogeneous LRT statistics (Hom-LRT) of models (3) and (5), MetaSKAT, and MetaBurdenWST at  $\alpha = 0.0001$ , when causal variants were only rare and the genetic effect is simulated as homogeneous. When Neg pct = 0, all causal variants had positive effects; when Neg pct = 20, 20%/80% of causal variants had negative/positive effects; when Neg pct = 50, 50%/50% of causal variants had negative/positive effects.

The functional linear models (1) and (4) are built to analyze data of multiple studies that may have different covariates and genetic variants. If all studies are genotyped at the same markers and they have the same covariates, then models (1) and (4) are the same as those of Fan *et al.*  (2013) if the genetic effects are homogeneous; *i.e.*,  $\beta_1(t) = \cdots = \beta_L(t)$ . In reality, the homogeneity assumption may not be valid in which case the functional linear models (1) and (4) are not a trivial extension of the models of Fan *et al.* (2013). In the analysis of the eight European cohorts,



**Figure 3** The empirical power of the homogeneous LRT statistics (Hom-LRT) of models (3) and (5), MetaSKAT, and MetaBurdenWST at  $\alpha = 0.0001$ , when causal variants were both rare and common and the genetic effect is simulated as heterogeneous. When Neg pct = 0, all causal variants had positive effects; when Neg pct = 20, 20%/80% of causal variants had negative/positive effects; when Neg pct = 50, 50%/50% of causal variants had negative/positive effects.



**Figure 4** The empirical power of the homogeneous LRT statistics (Hom-LRT) of models (3) and (5), MetaSKAT, and MetaBurdenWST at  $\alpha = 0.0001$ , when causal variants were only rare and the genetic effect is simulated as heterogeneous. When Neg pct = 0, all causal variants had positive effects; when Neg pct = 20, 20%/80% of causal variants had negative/positive effects; when Neg pct = 50, 50%/50% of causal variants had negative/positive effects.

more association signals are detected by Het-LRT and Het-F than by Hom-LRT and Hom-F, reflecting the presence of heterogeneity of the genetic effects.

In single studies with sample sizes of  $\leq$ 1000, LRT statistics of FLMs were found to inflate the type I error rates

while *F*-distributed statistics controlled type I error rates correctly (Fan *et al.* 2013). Hence, *F*-distributed statistics are recommended for small and moderate sample size single studies. In this article, we show that both *F*-distributed and LRT statistics control the type I error rates correctly

and their empirical power levels are similar when the sample sizes of combined multiple studies are large. In Fan *et al.* (2013), the LRT statistics were found to have correct type I error rates when the sample sizes were  $\geq$ 1500 in a single study. Therefore, the conclusion that both LRT and *F*-distributed statistics can be used for large sample meta-analysis in this article is consistent with the result of Fan *et al.* (2013).

The proposed method requires full genotype data; *i.e.*, we assume that individual genotype data are available from all studies. One reason is that we have this type of data in the eight European cohorts. The proposed approach is more powerful than MetaSKAT and MetaSKAT-O when genotype data are available from all studies, and the proposed method cannot meta-analyze summary statistics while MetaSKAT can. If summary statistics of functional regression models are available from different studies only using Fan et al. (2013), it is still an open question if those statistics can be used to meta-analyze the data of multiple studies. Note that the functional regressions are simply ordinary regressions after revising the theoretical functional models by functional data analysis techniques, and so the strategy of usual meta-analysis would be useful. Hence, it should be possible to use results from functional regression models for a meta-analysis across cohorts. However, the details are still waiting for further work.

With the rapid advance of high-throughput sequencing technologies (Mardis 2008; Ansorge 2009), more sequencing data from large cohorts will be collected and more meta-analyses will be performed in different populations. Association analysis has been increasingly carried out to identify risk or protective genetic variants of complex traits. It is important to develop powerful and efficient statistical methods to test for associations. Our metaanalysis FLMs provide an effective approach for the association analysis of complex traits.

#### Acknowledgments

Two anonymous reviewers and the editors, Chiara Sabatti and Gary Churchill, provided very good and insightful comments for us to improve the manuscript. We greatly thank the European cohort investigators for letting us analyze the data and use them as examples. Heather M. Stringham and Tanya M. Teslovich kindly sent us the data of the European cohorts and patiently answered many questions about the cohorts, which we greatly appreciated. We thank Seunggeun Lee for sending us the simulation program of SKAT and sequence data generated by Yun Li using the program COSI. This study utilized the high-performance computational capabilities of the Biowulf Linux cluster at the National Institutes of Health (http://biowulf.nih.gov). The methods proposed in this article are implemented by using the procedure of functional data analysis (fda) in the statistical package R. The R codes for data analysis and simulations are available at http://www.nichd.nih.gov/ about/org/diphr/bbb/software/fan/Pages/default.aspx. This study was supported by the Intramural Research Program of the Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health (NIH) (Ruzong Fan and Yifan Wang); by Wei Chen's NIH grants R01EY024226 and R01HG007358 and the University of Pittsburgh (Ruzong Fan is an unpaid collaborator on the grant R01EY024226); and by NIH grants R01HG006292 and R01HG006703 (to Yun Li).

#### Literature Cited

- Altshuler, D. M., E. S. Lander, L. Ambrogio, T. Bloom, K. Cibulskis et al., 2010 A map of human genome variation from population scale sequencing. Nature 467: 1061–1073.
- Ansorge, W. J., 2009 Next-generation DNA sequencing techniques. New Biotechnol. 25: 195–203.
- Cantor, R. M., K. Lange, and J. S. Sinsheimer, 2010 Prioritizing GWAS results: a review of statistical methods and recommendations for their application. Am. J. Hum. Genet. 86: 6–22.
- Chen, H., T. Lumley, J. Brody, N. L. Heard-Costa, C. S. Fox *et al.*, 2014 Sequence kernel association test for survival traits. Genet. Epidemiol. 38: 191–197.
- Cordell, H. J., and D. G. Clayton, 2002 A unified stepwise regression procedure for evaluating the relative effects of polymorphisms within a gene using case/control or family data: application to HLA in type 1 diabetes. Am. J. Hum. Genet. 70: 124–141.
- de Bakker, P. I. W., M. A. R. Ferreira, X. Jia, B. M. Neale, S. Raychaudhuri et al., 2008 Practical aspects of imputation-driven meta-analysis of genome-wide association studies. Hum. Mol. Genet. 17: 122–128.
- de Boor, C., 2001 Applied Mathematical Sciences 27, A Practical Guide to Splines, Revised Version. Springer-Verlag, New York.
- Evangelou, E., and J. P. A. Ioannidis, 2013 Meta-analysis methods for genome-wide association studies and beyond. Nat. Rev. Genet. 14: 379–389.
- Fan, R. Z., and M. M. Xiong, 2002 High resolution mapping of quantitative trait loci by linkage disequilibrium analysis. Eur. J. Hum. Genet. 10: 607–615.
- Fan, R. Z., J. S. Jung, and L. Jin, 2006 High resolution association mapping of quantitative trait loci, a population based approach. Genetics 172: 663–686.
- Fan, R. Z., Y. F. Wang, J. L. Mills, A. F. Wilson, J. E. Bailey-Wilson et al., 2013 Functional linear models for association analysis of quantitative traits. Genet. Epidemiol. 37: 726–742.
- Fan, R. Z., Y. F. Wang, J. L. Mills, T. C. Carter, I. Lobach *et al.*, 2014 Generalized functional linear models for case-control association studies. Genet. Epidemiol. 38: 622–637.
- Ferraty, F., and Y. Romain, 2010 The Oxford Handbook of Functional Data Analysis. Oxford University Press, New York.
- Fisher, R. A., 1918 The correlation between relatives on the supposition of Mendelian inheritance. Philos. Trans. R. Soc. Edinb. 52: 399–433.
- Hindorff, L. A., P. Sethupathy, H. A. Junkins, E. M. Ramos, J. P. Mehta *et al.*, 2009 Potential etiologic and functional implications of genome-wide association loci for human diseases and traits. Proc. Natl. Acad. Sci. USA 106: 9362–9367.
- Horváth, L., and P. Kokoszka, 2012 Inference for Functional Data With Applications. Springer-Verlag, New York.
- Hu, Y. J., S. I. Berndt, S. Gustafsson, and A. Ganna; Genetic Investigation of ANthropometric Traits (GIANT) Consortium *et al.*, 2013 Meta-analysis of gene-level associations for rare variants based on single-variant statistics. Am. J. Hum. Genet. 93: 42–53.

- International HapMap Consortium, 2007 A second generation human haplotype map of over 3.1 million SNPs. Nature 449: 851– 861.
- Ioannidis, J. P. A., N. A. Patsopoulos, and E. Evangelou, 2007 Heterogeneity in meta-analyses of genome-wide association investigations. PLoS ONE 2: e841.
- Lee, S., M. J. Emond, M. J. Bamshad, K. C. Barnes, M. J. Rieder *et al.*, 2012 Optimal unified approach for rare-variant association testing with application to small-sample case-control whole-exome sequencing studies. Am. J. Hum. Genet. 91: 224–237.
- Lee, S., T. M. Teslovich, M. Boehnke, and X. Lin, 2013 General framework for meta-analysis of rare variants in sequencing association studies. Am. J. Hum. Genet. 93: 42–53.
- Li, B., and S. M. Leal, 2008 Methods for detecting associations with rare variants for common diseases: application to analysis of sequence data. Am. J. Hum. Genet. 83: 311–321.
- Liu, D. J., G. M. Peloso, X. Zhan, O. L. Holmen, M. Zawistowski *et al.*, 2014 Meta-analysis of gene-level tests for rare variant association. Nat. Genet. 46: 200–204.
- Luo, L., Y. Zhu, and M. Xiong, 2012 Quantitative trait locus analysis for next-generation sequencing with the functional linear models. J. Med. Genet. 49: 513–524.
- Madsen, B. E., and S. R. Browning, 2009 A groupwise association test for rare mutations using a weighted sum statistic. PLoS Genet. 5: e1000384.
- Mardis, E. R., 2008 Next-generation DNA sequencing methods. Annu. Rev. Genomics Hum. Genet. 9: 387–402.
- Morris, A. P., and E. Zeggini, 2010 An evaluation of statistical approaches to rare variant analysis in genetic association studies. Genet. Epidemiol. 34: 188–193.
- Neale, B. M., M. A. Rivas, B. F. Voight, D. Altshuler, B. Devlin *et al.*, 2011 Testing for an unusual distribution of rare variants. PLoS Genet. 7: e1001322.

- Price, A. L., G. V. Kryukov, P. I. W. de Bakker, S. M. Purcell, J. Staples *et al.*, 2010 Pooled association tests for rare variants in exon-resequencing studies. Am. J. Hum. Genet. 86: 832–838.
- Ramsay, J. O., and B. W. Silverman, 2005 Functional Data Analysis, Ed. 2. Springer-Verlag, New York.
- Ramsay, J. O., G. Hooker, and S. Graves, 2009 Functional Data Analysis With R and Matlab. Springer-Verlag, New York.
- Ross, S. M., 1996 Stochastic Processes, Ed. 2. John Wiley & Sons, New York.
- Schaffner, S. F., C. Foo, S. Gabriel, D. Reich, M. J. Daly *et al.*, 2005 Calibrating a coalescent simulation of human genome sequence variation. Genome Res. 15: 1576–1583.
- Stahl, E. A., S. Raychaudhuri, E. F. Remmers, G. Xie, S. Eyre et al., 2010 Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci. Nat. Genet. 42: 508– 514.
- Tang, Z. Z., and D. Y. Lin, 2014 Meta-analysis of sequencing studies with heterogeneous genetic associations. Genet. Epidemiol. 38: 389–401.
- Wang, Y. F., A. Y. Liu, J. L. Mills, A. F. Wilson, and J. E. Bailey-Wilson *et al.*, 2015 Pleiotropy analysis of quantitative traits at gene level by multivariate functional linear models. Genet. Epidemiol. 39: 259–275.
- Weisberg, S., 2005 *Applied Linear Regression*, Ed. 3 (Wiley Series in Probability and Statistics). Wiley Interscience, Hoboken, NJ.
- Zeggini, E., and J. P. A. Ioannidis, 2009 Meta-analysis in genomewide association studies. Pharmacogenomics 10: 191–201.
- Zeggini, E., L. J. Scott, R. Saxena, B. F. Voight, J. L. Marchini *et al.*, 2008 Meta-analysis of genome-wide association data and large-scale replication identifies additional susceptibility loci for type 2 diabetes. Nat. Genet. 40: 638–645.

Communicating editor: C. Sabatti

# GENETICS

Supporting Information www.genetics.org/lookup/suppl/doi:10.1534/genetics.115.178343/-/DC1

## Gene Level Meta-Analysis of Quantitative Traits by Functional Linear Models

Ruzong Fan, Yifan Wang, Michael Boehnke, Wei Chen, Yun Li, Haobo Ren, Iryna Lobach, and Momiao Xiong

## Supplementary Materials I: "Gene Level Meta-analysis of Quantitative Traits by Functional Linear Models"

## Appendix A. Information and Extra Results of the Eight European Cohorts

For each of the eight European cohorts, we performed analysis for four lipid traits and 22 genes. The information of the 22 genes is given in Table S.1. The sample sizes of each trait are presented in Table S.2. The results of association analysis by Hom-F and Het-F are reported in Tables S.3 and S.4. Table S.1: Summary of 22 Genes and the Number of Genetic Variants in Each Gene Region by Mar. 2006 (NCBI36/hg18). The number of variants is the number of genetic variants in a region of Start (-5Kb) - End (+5Kb) Positions. \* The gene region of PCSK9 is (55277737, 55303114), and (55271537, 55286109) is the region in the database. # The length is the length of the region in bp.

Cono	Chromosome	Gene	Start $(-5Kb)$ - End $(+5Kb)$	Number of
Gene	Region	Positions (bp)	${\rm Positions}~({\rm Length}^{\#})$	Variants
PCSK9*	1	55277737 - 55303114	55271537 - 55286109 (14572)	74
APOB	2	21077806 - 21120450	21072806 - 21125450 (52644)	223
IGF2BP2	3	186844221 - 187025521	186839221 - 187030521 (191300)	231
CDKAL1	6	20642667 - 21340613	20637667 - 21345613 (707946)	560
JAZF1	7	27836718 - 28186962	27831718 - 28191962 (360244)	384
LPL	8	19840862 - 19869050	19835862 - 19874050 (38188)	212
CDKN2B	9	21992902 - 21999312	21987902 - 22004312 (16410)	64
CDC123	10	12277971 - 12332593	12272971 - 12337593 (64622)	265
IDE	10	94201421 - 94323832	94196421 - 94328832 (132411)	327
KIF11	10	94342805 - 94405132	94337805 - 94410132 (72327)	216
HHEX	10	94439661 - 94445388	94434661 - 94450388 (15727)	30
TCF7L2	10	114699999 - 114917426	114694999 - 114922426 (227427)	258
KCNQ1	11	2422797 - 2826916	2417797 - 2831916 (414119)	660
MTNR1B	11	92342437 - 92355596	92337437 - 92360596 (23159)	106
HMGA2	12	64504507 - 64646338	64499507 - 64651338 (151831)	214
TSPAN8	12	69805144 - 69838046	69800144 - $69843046$ ( $42902$ )	54
HNF1A	12	119900932 - 119924697	119895932 - 119929697 (33765)	71
OASL	12	119942478 - 119961428	119937478 - 119966428 (28950)	108
FTO	16	52295376 - 52705882	52290376 - 52710882 (420506)	191
LDLR	19	11061038 - 11105505	11056038 - 11110505 (54467)	43
APOE	19	50100879 - 50104490	50095879 - 50109490 (13611)	35
GIPR	19	50863342 - 50877557	50858342 - 50882557 (24215)	37

Table S.2: Sample Sizes of the Four Lipid Traits for Each of the Seven Studies.

Study	HDL	LDL	TG	CHOL
D2d-2007	2075	2074	2075	2075
DIAGEN	1470	1454	1470	1471
Dps	412	410	412	412
DRs EXTRA	1157	1157	1157	1157
FUSION Stage 2	2496	1892	2062	2500
METSIM	1346	1345	1346	1346
Norway	2484	2320	2487	2476
Total	11440	10652	11009	11437

Table S.3: Association Analysis of Lipid Traits in Eight European Cohorts by Homogeneous F-distributed Statistics (Hom-F), Hom-MetaSKAT-O, and Hom-MetaSKAT. The associations that attain a threshold significance of  $P < 3.1 \times 10^{-6}$ are marked by red (Liu *et al.* 2014). The results of "Basis of Both GVF and  $\beta_{\ell}(t)$ " were based on smoothing both GVF and genetic effect functions  $\beta_{\ell}(t)$  of model (3), and the results of "Basis of beta-Smooth Only" were based on smoothing  $\beta_{\ell}(t)$  only approach of model (5), the results of "Additive Model (7)" were based on the additive effect model (7), and the p-values of Hom-MetaSKAT and Hom-MetaSKAT-O were based of R package MetaSKAT. Abbreviation: GVF = Genetic Variant Function.

			P-val	ues of the Hom-	Ч		P-valı	ues of
Traits	Gene	Basis of Both (	<b>GVF and</b> $\beta_{\ell}(t)$	Basis of beta-	Smooth Only	Additive	Hom-	Meta-
		B-spline Basis	Fourier Basis	<b>B-spline Basis</b>	Fourier Basis	Model $(7)$	$\mathbf{SKAT}$	SKAT-O
HDL	LPL	$3.17  imes 10^{-6}$	$6.72 \times 10^{-9}$	$3.77 \times 10^{-6}$	$7.17 \times 10^{-7}$	$8.93 \times 10^{-4}$	$1.08 \times 10^{-3}$	$1.21 \times 10^{-3}$
	APOB	$3.63 imes10^{-9}$	$7.67  imes 10^{-4}$	$6.12 \times 10^{-8}$	$1.93 \times 10^{-4}$	$4.29 \times 10^{-5}$	$1.63 \times 10^{-2}$	$2.51  imes 10^{-2}$
IUI	APOE	$1.13  imes 10^{-85}$	$7.12  imes 10^{-89}$	$2.38 \times 10^{-81}$	$8.19 \times 10^{-88}$	$5.05 imes10^{-87}$	$1.18 imes10^{-43}$	$6.67  imes 10^{-44}$
	LDLR	$9.90  imes 10^{-15}$	$2.10 imes10^{-14}$	$6.14  imes 10^{-15}$	$1.13  imes 10^{-13}$	$9.47 \times 10^{-17}$	$1.03 imes10^{-10}$	$2.94 \times 10^{-10}$
	PCSK9	$2.39 \times 10^{-6}$	$6.04 \times 10^{-10}$	$1.72  imes 10^{-6}$	$1.37  imes 10^{-7}$	$3.62  imes 10^{-17}$	$6.18  imes 10^{-7}$	$2.00  imes 10^{-6}$
C E	APOE	$5.13  imes 10^{-6}$	$6.93 \times 10^{-6}$	$5.37  imes 10^{-7}$	$2.01 \times 10^{-6}$	$1.43 \times 10^{-6}$	$1.34 \times 10^{-3}$	$2.59  imes 10^{-3}$
5	LPL	$2.27 \times 10^{-11}$	$8.93 \times 10^{-13}$	$2.90 \times 10^{-11}$	$5.20 imes10^{-14}$	$6.67  imes 10^{-7}$	$1.78 \times 10^{-5}$	$1.77 \times 10^{-5}$
	APOB	$2.11  imes 10^{-8}$	$7.97  imes 10^{-3}$	$2.30  imes 10^{-7}$	$1.20  imes 10^{-4}$	$8.08  imes 10^{-8}$	$6.17  imes 10^{-2}$	$1.00  imes 10^{-1}$
	APOE	$1.33 \times 10^{-52}$	$2.12  imes 10^{-52}$	$6.24 \times 10^{-48}$	$8.37 \times 10^{-51}$	$1.03 imes10^{-50}$	$9.08 \times 10^{-23}$	$2.15 \times 10^{-22}$
	<b>HNF1A</b>	$1.08 \times 10^{-1}$	$1.85 \times 10^{-2}$	$9.00 \times 10^{-3}$	$2.99 \times 10^{-6}$	$1.77  imes 10^{-2}$	$1.89 \times 10^{-1}$	$2.77  imes 10^{-1}$
	LDLR	$8.93 \times 10^{-11}$	$9.47  imes 10^{-10}$	$9.32 \times 10^{-10}$	$7.33 \times 10^{-9}$	$2.43 \times 10^{-12}$	$3.43 \times 10^{-7}$	$1.15  imes 10^{-6}$

Table S.4: Association Analysis of Lipid Traits in Eight European Cohorts by Heterogeneous F-distributed Statistics (Het-F), Het-MetaSKAT-O, and Het-MetaSKAT. The associations that attain a threshold significance of  $P < 3.1 \times 10^{-6}$  are marked by red (Liu *et al.* 2014). The results of "Basis of Both GVF and  $\beta_{\ell}(t)$ " were based on smoothing both GVF and genetic effect functions  $\beta_{\ell}(t)$  of model (3), and the results of "Basis of beta-Smooth Only" were based on smoothing  $\beta_{\ell}(t)$  only approach of model (5), the results of "Additive Model (6)" were based on the additive effect model (6), and the p-values of Het-MetaSKAT and Het-MetaSKAT-O were based of R package MetaSKAT. Abbreviation: GVF = Genetic Variant Function.

			P-va	lues of the Het-l	Ē.		P-valı	tes of
Traits	Gene	Basis of Both	<b>GVF and</b> $\beta_{\ell}(t)$	Basis of beta-	Smooth Only	Additive	Het-N	Aeta-
		<b>B-spline Basis</b>	Fourier Basis	<b>B-spline Basis</b>	Fourier Basis	Model (6)	SKAT	SKAT-O
	APOB	$7.29  imes 10^{-11}$	$6.69  imes 10^{-8}$	$7.29  imes 10^{-11}$	$6.69  imes 10^{-8}$	$5.80  imes 10^{-6}$	$7.61  imes 10^{-2}$	$1.40 \times 10^{-1}$
	APOE	$1.90  imes 10^{-78}$	$1.30  imes 10^{-76}$	$1.90  imes 10^{-78}$	$1.30 \times 10^{-76}$	$9.51  imes 10^{-76}$	$2.23 \times 10^{-33}$	$1.28 \times 10^{-38}$
	CDC123	$2.04 \times 10^{-6}$	$4.57 \times 10^{-8}$	$2.04  imes 10^{-6}$	$4.57  imes 10^{-8}$	$6.22 \times 10^{-3}$	$2.54 \times 10^{-1}$	$4.19 \times 10^{-1}$
	<b>CDKAL1</b>	$6.11  imes 10^{-7}$	$6.77  imes 10^{-8}$	$6.11  imes 10^{-7}$	$6.77  imes 10^{-8}$	$9.21  imes 10^{-3}$	$3.74 \times 10^{-1}$	$5.81  imes 10^{-1}$
	CDKN2B	$7.97 \times 10^{-7}$	$1.20  imes 10^{-5}$	$7.97  imes 10^{-7}$	$1.46 \times 10^{-5}$	$1.88 \times 10^{-5}$	$7.46 \times 10^{-1}$	$9.20 \times 10^{-1}$
LDL	FTO	$2.46 \times 10^{-6}$	$1.29 \times 10^{-5}$	$2.46 \times 10^{-6}$	$1.29  imes 10^{-5}$	$4.43 \times 10^{-4}$	$1.11  imes 10^{-2}$	$2.23 \times 10^{-2}$
	<b>HNF1A</b>	$8.93 \times 10^{-11}$	$7.60  imes 10^{-8}$	$8.93  imes 10^{-11}$	$3.26  imes 10^{-8}$	$1.61 \times 10^{-10}$	$1.31 \times 10^{-1}$	$2.26 \times 10^{-1}$
	LDLR	$7.96  imes 10^{-9}$	$1.95  imes 10^{-9}$	$1.12  imes 10^{-8}$	$1.72 \times 10^{-9}$	$3.19  imes 10^{-9}$	$4.27 \times 10^{-7}$	$4.93 \times 10^{-7}$
	OASL	$1.41 \times 10^{-7}$	$5.25 \times 10^{-6}$	$1.41 \times 10^{-7}$	$7.48  imes 10^{-6}$	$1.11  imes 10^{-5}$	$1.20 \times 10^{-1}$	$8.81  imes 10^{-2}$
	PCSK9	$6.51  imes 10^{-9}$	$1.70  imes 10^{-12}$	$6.51  imes 10^{-9}$	$3.55 imes10^{-11}$	$9.92 \times 10^{-12}$	$9.03  imes 10^{-4}$	$2.09  imes 10^{-3}$
	TSPAN8	$8.68 \times 10^{-9}$	$2.17  imes 10^{-10}$	$1.06  imes 10^{-10}$	$1.38 \times 10^{-10}$	$2.20  imes 10^{-10}$	$6.47 \times 10^{-2}$	$1.22 \times 10^{-1}$
$\mathrm{TG}$	TPL	$1.43 \times 10^{-5}$	$1.11  imes 10^{-6}$	$1.43 \times 10^{-5}$	$1.11 \times 10^{-6}$	$6.70  imes 10^{-5}$	$3.38 \times 10^{-6}$	$6.30 \times 10^{-6}$
	APOB	$2.09  imes 10^{-12}$	$5.30 imes10^{-10}$	$2.09  imes 10^{-12}$	$5.30  imes 10^{-10}$	$2.93 \times 10^{-9}$	$6.04 \times 10^{-2}$	$1.12 \times 10^{-1}$
	APOE	$9.35  imes 10^{-54}$	$4.49 \times 10^{-51}$	$9.35  imes 10^{-54}$	$4.49 \times 10^{-51}$	$5.85  imes 10^{-51}$	$2.76 \times 10^{-20}$	$3.08 \times 10^{-22}$
	CDC123	$2.66  imes 10^{-6}$	$1.79  imes 10^{-6}$	$2.66  imes 10^{-6}$	$1.79  imes 10^{-6}$	$1.21 \times 10^{-2}$	$7.13  imes 10^{-1}$	$8.97  imes 10^{-1}$
	<b>CDKAL1</b>	$5.74  imes 10^{-8}$	$4.01 \times 10^{-9}$	$5.74  imes 10^{-8}$	$4.01 \times 10^{-9}$	$2.30 \times 10^{-4}$	$1.17  imes 10^{-1}$	$2.06 \times 10^{-1}$
	CDKN2B	$2.20  imes 10^{-7}$	$1.71 \times 10^{-6}$	$2.20  imes 10^{-7}$	$8.20  imes 10^{-7}$	$1.57  imes 10^{-6}$	$8.76  imes 10^{-1}$	$6.39 \times 10^{-1}$
	FTO	$3.43 \times 10^{-7}$	$1.88 \times 10^{-6}$	$3.43 \times 10^{-7}$	$1.88 \times 10^{-6}$	$9.52 \times 10^{-7}$	$9.84 \times 10^{-3}$	$1.99 \times 10^{-2}$
IOHO	<b>HNF1A</b>	$6.09 \times 10^{-11}$	$1.29 \times 10^{-8}$	$6.09 \times 10^{-11}$	$1.20 \times 10^{-8}$	$6.62  imes 10^{-10}$	$4.33 \times 10^{-1}$	$5.38 \times 10^{-1}$
	IDE	$6.78 \times 10^{-5}$	$1.74 \times 10^{-6}$	$6.78 \times 10^{-5}$	$1.74 \times 10^{-6}$	$1.08 \times 10^{-4}$	$2.30 \times 10^{-1}$	$3.86 \times 10^{-1}$
	JAZF1	$2.56 \times 10^{-6}$	$4.91 \times 10^{-6}$	$2.56  imes 10^{-6}$	$4.91 \times 10^{-6}$	$9.79 \times 10^{-4}$	$9.52 \times 10^{-2}$	$1.71 \times 10^{-1}$
	KIF11	$1.15  imes 10^{-6}$	$8.67  imes 10^{-7}$	$1.15  imes 10^{-6}$	$8.67  imes 10^{-7}$	$1.72 \times 10^{-5}$	$2.77 \times 10^{-1}$	$4.40 \times 10^{-1}$
	LDLR	$2.81 \times 10^{-6}$	$4.98 \times 10^{-8}$	$3.73 \times 10^{-6}$	$4.77 \times 10^{-8}$	$9.10  imes 10^{-8}$	$4.77 \times 10^{-4}$	$2.28  imes 10^{-5}$
	<b>MTNR1B</b>	$8.07  imes 10^{-7}$	$7.59 \times 10^{-7}$	$8.07  imes 10^{-7}$	$1.80  imes 10^{-7}$	$7.96 \times 10^{-7}$	$4.16 \times 10^{-2}$	$7.48 \times 10^{-2}$
	OASL	$1.36  imes 10^{-7}$	$1.26  imes 10^{-7}$	$1.36  imes 10^{-7}$	$1.91  imes 10^{-7}$	$1.51  imes 10^{-7}$	$3.11 \times 10^{-1}$	$5.06 \times 10^{-2}$
	PCSK9	$2.11 \times 10^{-5}$	$2.61  imes 10^{-6}$	$2.11 \times 10^{-5}$	$1.00  imes 10^{-5}$	$7.69 \times 10^{-7}$	$1.89 \times 10^{-2}$	$3.72 \times 10^{-2}$
	TSPAN8	$1.46  imes 10^{-10}$	$3.38 \times 10^{-13}$	$4.54 \times 10^{-13}$	$4.24 \times 10^{-13}$	$4.02 \times 10^{-13}$	$9.43 \times 10^{-2}$	$1.74 \times 10^{-1}$

Table S.5: Results of Separate Association Analysis of Lipid Traits in the Individual European Studies in the Regions of APOE and LDLR Genes Using the F-distributed Statistics. The associations that attain a threshold significance of  $P < 3.1 \times 10^{-6}$ are marked by red (Liu *et al.* 2014). The results of "Basis of both GVF and  $\beta(t)$ " were based on smoothing both GVF and genetic effect functions  $\beta(t)$  of fixed effect model, the results of "Basis of beta-Smooth Only" were based on beta-smooth only model (Fan et al. 2013), the results of "Additive Model (6)" were based on the additive effect model (6) to analyze study by study (i.e., L = 1), and the p-values of SKAT-O Were Based of R Package SKAT. Abbreviation: GVF = Genetic Variant Function.

				<i>P</i> -values of th	ne F-distributed	Statistics		<i>P</i> -values
$\mathbf{Study}$	Gene	Traits	Basis of both (	<b>GVF</b> and $\beta(t)$	Basis of beta-	Smooth Only	Additive	of
			<b>B-spline Basis</b>	Fourier Basis	<b>B-spline Basis</b>	Fourier Basis	Model (6)	SKAT-O
2006 Per	A DOF	LDL	$1.89  imes 10^{-25}$	$9.02  imes 10^{-25}$	$1.89  imes 10^{-25}$	$9.02  imes 10^{-25}$	$2.85  imes 10^{-24}$	$5.87  imes 10^{-13}$
1002-020	ALUE	CHOL	$9.09  imes 10^{-18}$	$3.01  imes 10^{-17}$	$9.09  imes 10^{-18}$	$3.01 \times 10^{-17}$	$7.97  imes 10^{-17}$	$1.72 \times 10^{-9}$
FUSION	A D O F	LDL	$4.34 \times 10^{-10}$	$2.24 \times 10^{-11}$	$4.34 \times 10^{-10}$	$2.24 \times 10^{-11}$	$3.42 \times 10^{-11}$	$8.61  imes 10^{-14}$
Stage 2	ALUE	CHOL	$1.34 \times 10^{-12}$	$4.92 \times 10^{-13}$	$1.34 \times 10^{-12}$	$4.92 \times 10^{-13}$	$8.70  imes 10^{-13}$	$1.64 \times 10^{-12}$
N	A D O F	LDL	$3.79  imes 10^{-28}$	$1.90 \times 10^{-27}$	$3.79  imes 10^{-28}$	$1.90 \times 10^{-27}$	$6.05  imes 10^{-27}$	$6.21  imes 10^{-6}$
INUT WAY	ALUE	CHOL	$2.12 \times 10^{-14}$	$6.15 \times 10^{-14}$	$2.12 \times 10^{-14}$	$6.15 \times 10^{-14}$	$1.35  imes 10^{-13}$	$3.00 \times 10^{-3}$
DIAGEN	APOE	LDL	$7.84  imes 10^{-7}$	$3.31 \times 10^{-6}$	$7.84  imes 10^{-7}$	$3.31  imes 10^{-6}$	$5.76  imes 10^{-6}$	$2.37  imes 10^{-1}$
NETCINI	APOE	LDL	$1.85  imes 10^{-5}$	$1.98  imes 10^{-5}$	$1.85  imes 10^{-5}$	$1.98  imes 10^{-5}$	$3.45  imes 10^{-5}$	$1.25 \times 10^{-4}$
	LDLR	CHOL	$3.47 \times 10^{-4}$	$2.97 \times 10^{-6}$	$3.47  imes 10^{-4}$	$2.97 \times 10^{-6}$	$5.67  imes 10^{-6}$	$5.79  imes 10^{-3}$

## Appendix B. Empirical Power Figures of Heterogeneous Likelihood Ratio Tests (Het-LRT)

In this section of the **Supplementary Materials I**, more empirical power results are presented based on heterogeneous likelihood ratio tests (Het-LRT).



Figure S.1: The Empirical Power of the Heterogeneous LRT Statistics (Het-LRT) of the Models (3) and (5), MetaSKAT, and MetaBurdenWST at  $\alpha = 0.0001$ , When Causal Variants Were Both Rare and Common and the Genetic Effect is Simulated as Homogeneous. When Neg pct = 0, All Causal Variants Had Positive Effects; When Neg pct = 20, 20%/80% Causal Variants Had Negative/Positive Effects; When Neg pct = 50, 50%/50% Causal Variants Had Negative/Positive Effects.



Figure S.2: The Empirical Power of the Heterogeneous LRT Statistics (Het-LRT) of the Models (3) and (5), MetaSKAT, and MetaBurdenWST at  $\alpha = 0.0001$ , When Causal Variants Were Only Rare and the Genetic Effect is Simulated as Homogeneous. When Neg pct = 0, All Causal Variants Had Positive Effects; When Neg pct = 20, 20%/80% Causal Variants Had Negative/Positive Effects; When Neg pct = 50, 50%/50% Causal Variants Had Negative/Positive Effects.



Figure S.3: The Empirical Power of the Heterogeneous LRT Statistics (Het-LRT) of the Models (3) and (5), MetaSKAT, and MetaBurdenWST at  $\alpha = 0.0001$ , When Causal Variants Were Both Rare and Common and the Genetic Effect is Simulated as Heterogeneous. When Neg pct = 0, All Causal Variants Had Positive Effects; When Neg pct = 20, 20%/80% Causal Variants Had Negative/Positive Effects; When Neg pct = 50, 50%/50% Causal Variants Had Negative/Positive Effects.



Figure S.4: The Empirical Power of the Heterogeneous LRT Statistics (Het-LRT) of the Models (3) and (5), MetaSKAT, and MetaBurdenWST at  $\alpha = 0.0001$ , When Causal Variants Were Only Rare and the Genetic Effect is Simulated as Heterogeneous. When Neg pct = 0, All Causal Variants Had Positive Effects; When Neg pct = 20, 20%/80% Causal Variants Had Negative/Positive Effects; When Neg pct = 50, 50%/50% Causal Variants Had Negative/Positive Effects.